,Rank,NCTId,BriefTitle,OrgStudyId,LeadSponsorName,LocationCountry
42,43,NCT04879628,Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis,ACT16877,Sanofi,United States
42,43,NCT04879628,Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis,ACT16877,Sanofi,Bulgaria
42,43,NCT04879628,Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis,ACT16877,Sanofi,Canada
42,43,NCT04879628,Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis,ACT16877,Sanofi,Czechia
42,43,NCT04879628,Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis,ACT16877,Sanofi,Spain
42,43,NCT04879628,Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis,ACT16877,Sanofi,Ukraine
45,46,NCT04869358,Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab,COMB157GDE01,Novartis Pharmaceuticals,Germany
48,49,NCT04856345,Running Title: Walking to Music and in Silence on a Treadmill,B1152020000021,Hasselt University,Belgium
49,50,NCT04855617,Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis,20-00041,NYU Langone Health,United States
51,52,NCT04843774,Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA),21-00206,NYU Langone Health,United States
67,68,NCT04788615,Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS,COMB157G3301,Novartis Pharmaceuticals,France
67,68,NCT04788615,Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS,COMB157G3301,Novartis Pharmaceuticals,Germany
67,68,NCT04788615,Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS,COMB157G3301,Novartis Pharmaceuticals,Spain
72,73,NCT04767698,Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis,IRB00246563,Johns Hopkins University,United States
74,75,NCT04756700,Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis,FR-MSG-11654,Biogen,France
80,81,NCT04742400,"Tolebrutinib, a Brain-penetrant Bruton s Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis",210010,National Institute of Neurological Disorders and Stroke (NINDS),United States
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,United States
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Argentina
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Belgium
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Brazil
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Bulgaria
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Canada
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Czechia
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Denmark
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,France
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Germany
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Greece
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Hungary
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Italy
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Mexico
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Peru
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Poland
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Portugal
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Puerto Rico
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Russian Federation
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Spain
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Switzerland
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Turkey
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,Ukraine
109,110,NCT04548999,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",BN42083,Hoffmann-La Roche,United Kingdom
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,United States
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Argentina
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Australia
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Belgium
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Brazil
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Canada
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Czechia
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Denmark
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,France
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Germany
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Greece
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Hungary
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Israel
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Italy
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Mexico
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Netherlands
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Peru
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Poland
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Portugal
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Russian Federation
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Spain
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Switzerland
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Turkey
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,Ukraine
115,116,NCT04544436,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",BN42082,Hoffmann-La Roche,United Kingdom
118,119,NCT04538872,Learning Strategies for Improving Dual Task Performance in Multiple Sclerosis,StraDiMS-001,Hasselt University,Belgium
134,135,NCT04480853,Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis,CFTY720DTW03,Novartis Pharmaceuticals,Taiwan
146,147,NCT04410965,Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks,BDR16019,Sanofi,China
154,155,NCT04356339,US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector,20756,Bayer,United States
186,187,NCT04191772,The Impact of Training on Sitting Time and Brain Volumes in Multiple Sclerosis.,EXIMS,Hasselt University,Belgium
192,193,NCT04171310,Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects,BEX16018,Sanofi,United Kingdom
194,195,NCT04158063,Cognitive-motor Interference in Persons With MS,MCS-IV-CMI&DTT-01,Hasselt University,Belgium
197,198,NCT04147052,iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis,IRB00116581,Johns Hopkins University,United States
199,200,NCT04145284,Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS,888MS007,Biogen,United States
199,200,NCT04145284,Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS,888MS007,Biogen,Germany
201,202,NCT04142853,"Underlying Causes and Related Factors, and Rehabilitation Approaches",B707201835771,Hasselt University,Belgium
202,203,NCT04142008,Walk With Me: a Mobile Application to Improve Walking in Persons With MS,B9115201836734,Hasselt University,Belgium
211,212,NCT04123353,Scan-Rescan Sub-Study of MS PATHS,888MS004,Biogen,United States
224,225,NCT04075266,A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis,WA39085,Hoffmann-La Roche,United States
224,225,NCT04075266,A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis,WA39085,Hoffmann-La Roche,Italy
224,225,NCT04075266,A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis,WA39085,Hoffmann-La Roche,Poland
229,230,NCT04054050,Bright Light Therapy for Sleep Disturbance in People With Multiple Sclerosis,IRB00222887,Johns Hopkins University,United States
239,240,NCT04025554,Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis,190124,National Institute of Neurological Disorders and Stroke (NINDS),United States
246,247,NCT03983681,Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS,R-1045-18,Kessler Foundation,United States
258,259,NCT03934489,Emotion Regulation Skills Training for Individuals With MS and Their Support Partners,IRB00199623,Johns Hopkins University,United States
261,262,NCT03931278,Sonification Embodied Associations,SEA-001,Hasselt University,Belgium
264,265,NCT03926637,Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis,US-MSG-18-11424,Biogen,United States
264,265,NCT03926637,Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis,US-MSG-18-11424,Biogen,Czechia
264,265,NCT03926637,Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis,US-MSG-18-11424,Biogen,France
264,265,NCT03926637,Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis,US-MSG-18-11424,Biogen,Switzerland
266,267,NCT03919058,Sit Less or Exercise More: Impact on Cardiometabolic Health in MS,RST-MS,Hasselt University,Belgium
277,278,NCT03873389,Ocrelizumab Effects on the Metabolome in MS,IRB00205181,Johns Hopkins University,United States
279,280,NCT03860675,Assessment of Walking-related Fatigability in Patients With Multiple Sclerosis.,FaVG-001,Hasselt University,Belgium
282,283,NCT03853746,Short-term B-cell Depletion in Relapsing Multiple Sclerosis,IRB00201318,Johns Hopkins University,United States
286,287,NCT03838770,tDCS for the Management of Multiple Sclerosis Related Fatigue,18-01406,NYU Langone Health,United States
293,294,NCT03808142,PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon,20263,Bayer,Germany
297,298,NCT03803800,Periodized Rehabilitation and Beta-alanine Supplementation in Multiple Sclerosis,16.111/REVA16.14,Hasselt University,Belgium
335,336,NCT03658668,Study of the Combined Effect of Transcranial Direct Current Stimulation (tDCS) and Physical Activity on Gait and Functional Mobility in Participants With Multiple Sclerosis,18-00534,NYU Langone Health,United States
341,342,NCT03647904,The SEMS Project: Staying Employed With MS,E-944-16,Kessler Foundation,United States
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Argentina
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Belgium
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Brazil
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Bulgaria
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Canada
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Croatia
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Czechia
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Denmark
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Estonia
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Finland
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,France
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Ireland
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Italy
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Kuwait
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Mexico
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Netherlands
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Norway
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Poland
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Portugal
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Slovakia
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Slovenia
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Spain
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Sweden
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,Turkey
354,355,NCT03599245,This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),MN39158,Hoffmann-La Roche,United Kingdom
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Austria
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Belgium
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Brazil
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Bulgaria
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Chile
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Colombia
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Dominican Republic
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Egypt
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Italy
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Kuwait
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Montenegro
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Netherlands
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Panama
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Paraguay
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Poland
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Portugal
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Qatar
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Romania
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Russian Federation
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Saudi Arabia
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Serbia
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Slovakia
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Spain
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,Turkey
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,United Arab Emirates
358,359,NCT03593590,Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis,MN39889,Hoffmann-La Roche,United Kingdom
360,361,NCT03589105,"A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting",ML40359,Hoffmann-La Roche,France
362,363,NCT03577977,Betaferon Use in Children and Adolescents With Multiple Sclerosis,2008/01743,Bayer,Russian Federation
365,366,NCT03564496,Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRI,18-00548,NYU Langone Health,United States
366,367,NCT03560739,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,COMB157G2102,Novartis Pharmaceuticals,United States
366,367,NCT03560739,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,COMB157G2102,Novartis Pharmaceuticals,Austria
366,367,NCT03560739,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,COMB157G2102,Novartis Pharmaceuticals,Bulgaria
366,367,NCT03560739,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,COMB157G2102,Novartis Pharmaceuticals,Czechia
366,367,NCT03560739,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,COMB157G2102,Novartis Pharmaceuticals,Estonia
366,367,NCT03560739,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,COMB157G2102,Novartis Pharmaceuticals,Latvia
366,367,NCT03560739,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,COMB157G2102,Novartis Pharmaceuticals,Lithuania
366,367,NCT03560739,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,COMB157G2102,Novartis Pharmaceuticals,Russian Federation
366,367,NCT03560739,A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients,COMB157G2102,Novartis Pharmaceuticals,Spain
376,377,NCT03508414,Nutritional Approaches in Multiple Sclerosis,NAMS-study,"Charite University, Berlin, Germany",Germany
381,382,NCT03499314,A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS),17-00522,NYU Langone Health,United States
402,403,NCT03373344,Remediation of Emotional Processing Deficits in MS,R-920-16,Kessler Foundation,United States
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Austria
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Belgium
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Czechia
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Denmark
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Finland
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",France
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Greece
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Hungary
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Italy
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Lithuania
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Netherlands
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Norway
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Poland
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Portugal
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Slovakia
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Spain
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",Sweden
404,405,NCT03369665,Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS),MS700568_0021,"Merck KGaA, Darmstadt, Germany",United Kingdom
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",Australia
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",Austria
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",Canada
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",Czechia
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",Finland
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",France
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",Germany
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",Hungary
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",Israel
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",Italy
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",Poland
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",Spain
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",Sweden
410,411,NCT03364036,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),MS700568_0022,"Merck KGaA, Darmstadt, Germany",United Kingdom
425,426,NCT03281330,Effect of Motor Entrainment to Auditory Cues and Music During Walking on Quality of Movement and Perceived Fatigue in Persons With Multiple Sclerosis (PwMS),B67021629797,Hasselt University,Belgium
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Austria
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Belgium
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Canada
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Czechia
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Denmark
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Finland
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,France
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Germany
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Hungary
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Israel
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Italy
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Norway
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Poland
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Portugal
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Spain
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Sweden
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,Switzerland
426,427,NCT03269175,BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies,19215,Bayer,United Kingdom
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,United States
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,Australia
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,Belgium
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,Canada
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,Czechia
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,France
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,Germany
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,Hungary
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,Israel
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,Italy
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,Netherlands
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,Poland
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,Spain
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,Switzerland
436,437,NCT03222973,Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS),215MS202,Biogen,United Kingdom
443,444,NCT03198351,An Observational Study on Teriflunomide-exposed Pregnancies,OBS13499,Sanofi,United States
443,444,NCT03198351,An Observational Study on Teriflunomide-exposed Pregnancies,OBS13499,Sanofi,Canada
449,450,NCT03174379,A Study to Analyze the Effect of Acupuncture on Mobility And Quality of Life in Multiple Sclerosis,15-00440,NYU Langone Health,United States
463,464,NCT03134573,Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study,18462,Bayer,Germany
482,483,NCT03028675,pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress,16-01434,NYU Langone Health,United States
497,498,NCT02969304,Study of Utilization Patterns of Dimethyl Fumarate in Germany,109MS409,Biogen,Germany
501,502,NCT02952911,Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study,MA30162,Hoffmann-La Roche,United States
501,502,NCT02952911,Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study,MA30162,Hoffmann-La Roche,Spain
502,503,NCT02949908,MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS),EMR200136_597,"Merck KGaA, Darmstadt, Germany",Germany
536,537,NCT02784210,Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques,160114,National Institute of Neurological Disorders and Stroke (NINDS),United States
538,539,NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),109MS421,Biogen,United States
538,539,NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),109MS421,Biogen,Argentina
538,539,NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),109MS421,Biogen,Australia
538,539,NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),109MS421,Biogen,Canada
538,539,NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),109MS421,Biogen,Croatia
538,539,NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),109MS421,Biogen,Czech Republic
538,539,NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),109MS421,Biogen,France
538,539,NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),109MS421,Biogen,Germany
538,539,NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),109MS421,Biogen,Hungary
538,539,NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),109MS421,Biogen,Italy
538,539,NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),109MS421,Biogen,Spain
538,539,NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),109MS421,Biogen,Switzerland
538,539,NCT02776072,Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS),109MS421,Biogen,United Kingdom
545,546,NCT02749396,EPID Multiple Sclerosis Pregnancy Study,18219,Bayer,Finland
547,548,NCT02746705,Pilot Study of Transcranial Direct Current Stimulation (tDCS),15-01189,NYU Langone Health,United States
549,550,NCT02740361,Online Program to Reduce Depression in MS,IDEMS,"Charite University, Berlin, Germany",United States
549,550,NCT02740361,Online Program to Reduce Depression in MS,IDEMS,"Charite University, Berlin, Germany",Germany
560,561,NCT02688231,Task-oriented Upper Limb Training in MS,S58587,Hasselt University,Belgium
565,566,NCT02665221,"Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY",15-00173,NYU Langone Health,United States
567,568,NCT02664324,MSPT Device Usability Study,888MS003,Biogen,United States
568,569,NCT02659956,Pathological Basis of MRI Signal Changes in Multiple Sclerosis,160055,National Institute of Neurological Disorders and Stroke (NINDS),United States
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,ALK8700-A301,Biogen,United States
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,ALK8700-A301,Biogen,Belgium
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,ALK8700-A301,Biogen,Bulgaria
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,ALK8700-A301,Biogen,Canada
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,ALK8700-A301,Biogen,Germany
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,ALK8700-A301,Biogen,Poland
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,ALK8700-A301,Biogen,Russian Federation
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,ALK8700-A301,Biogen,Serbia
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,ALK8700-A301,Biogen,Spain
572,573,NCT02634307,A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1,ALK8700-A301,Biogen,Ukraine
593,594,NCT02521545,Single-Dose Study of a New Formulation of BIIB061,231HV103,Biogen,United States
594,595,NCT02519413,Tecfidera Lymphocyte Chart Review,109MS419,Biogen,United States
597,598,NCT02511028,"In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging",150156,National Institute of Neurological Disorders and Stroke (NINDS),United States
598,599,NCT02509897,Normobaric Hypoxic Training and Multiple Sclerosis,EpoxiMet,"Charite University, Berlin, Germany",Germany
601,602,NCT02496416,Comparison of Two Physical Activity Interventions in Individuals With Multiple Sclerosis,R-876-15,Kessler Foundation,United States
602,603,NCT02493166,Dual Task Cost in the Upper Limb in Persons With Multiple Sclerosis,2015-PFE-JRA01,Hasselt University,Belgium
605,606,NCT02486640,Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon,18016,Bayer,Germany
613,614,NCT02454907,The Use of Technology to Improve MS Clinical Trials and Patient Care,NA_00083614,Johns Hopkins University,United States
620,621,NCT02428231,Tecfidera Slow-Titration Study,109MS416,Biogen,United States
620,621,NCT02428231,Tecfidera Slow-Titration Study,109MS416,Biogen,Belgium
620,621,NCT02428231,Tecfidera Slow-Titration Study,109MS416,Biogen,Czech Republic
620,621,NCT02428231,Tecfidera Slow-Titration Study,109MS416,Biogen,Italy
629,630,NCT02410278,Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera,109MS414,Biogen,United States
640,641,NCT02386566,Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab,CHE-TYS-12-10341,Biogen,Switzerland
649,650,NCT02343159,Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.,109MS413,Biogen,United States
651,652,NCT02339688,Psychometric Properties Mobility Measures MS,ML10457- S56574,Hasselt University,Belgium
652,653,NCT02339675,Psychometric Properties Upper Limb Function Measures Multiple Sclerosis,ML10456-S56575,Hasselt University,Belgium
663,664,NCT02301260,Speed of Processing Training to Improve Cognition in Multiple Sclerosis,RG 4997A5/1,Kessler Foundation,United States
664,665,NCT02297932,Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes,843-14,Kessler Foundation,United States
674,675,NCT02269930,Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers,105HV105,Biogen,United States
683,684,NCT02232061,"Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks",CFTY720D2409,Novartis Pharmaceuticals,Belgium
683,684,NCT02232061,"Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks",CFTY720D2409,Novartis Pharmaceuticals,Germany
683,684,NCT02232061,"Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks",CFTY720D2409,Novartis Pharmaceuticals,Italy
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,218MS305,Biogen,United States
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,218MS305,Biogen,Bulgaria
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,218MS305,Biogen,Czech Republic
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,218MS305,Biogen,Finland
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,218MS305,Biogen,Italy
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,218MS305,Biogen,Lithuania
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,218MS305,Biogen,Netherlands
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,218MS305,Biogen,Poland
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,218MS305,Biogen,Russian Federation
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,218MS305,Biogen,Serbia
688,689,NCT02219932,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,218MS305,Biogen,United Kingdom
692,693,NCT02201849,"A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults",ALK8700-001,Biogen,United States
706,707,NCT02121444,"BAY86-5046 (Betaseron), Non Interventional Studies",17101,Bayer,Germany
709,710,NCT02117050,RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate,EMR200136-586,EMD Serono,United States
718,719,NCT02081508,Consolidation & Interference in Multiple Sclerosis,R-800-13,Kessler Foundation,United States
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,United States
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Argentina
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Australia
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Austria
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Canada
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Czechia
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Denmark
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,France
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Germany
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Hungary
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Ireland
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Italy
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Netherlands
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,New Zealand
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Norway
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Poland
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Portugal
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Puerto Rico
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Slovakia
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Spain
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,Switzerland
721,722,NCT02047097,Dimethyl Fumarate (DMF) Observational Study,109MS401,Biogen,United Kingdom
722,723,NCT02046629,A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers,PKM12788,Sanofi,China
726,727,NCT02032589,Testing the Efficacy of Self-Generation Treatment Protocol,698-11 GE,Kessler Foundation,United States
727,728,NCT02030197,"Impact of CRISP on Self-Efficacy, Loneliness, and Depression",S14-00572,NYU Langone Health,United States
741,742,NCT01973491,ATX-MS-1467 in Multiple Sclerosis,200166-001,"Merck KGaA, Darmstadt, Germany",Germany
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,United States
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,Austria
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,Belgium
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,Canada
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,Chile
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,Finland
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,France
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,Germany
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,Greece
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,Italy
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,Norway
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,Spain
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,Sweden
755,756,NCT01895335,Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients,LPS13567,Sanofi,United Kingdom
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,United States
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Australia
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Austria
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Belarus
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Brazil
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Bulgaria
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Canada
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Croatia
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Estonia
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,France
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Germany
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Italy
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Latvia
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Lithuania
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Mexico
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Netherlands
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Poland
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Puerto Rico
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Romania
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Russian Federation
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Serbia
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Slovakia
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Spain
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Sweden
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Turkey
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,Ukraine
756,757,NCT01892722,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,CFTY720D2311,Novartis Pharmaceuticals,United Kingdom
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,CAIN457B2203,Novartis Pharmaceuticals,Belgium
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,CAIN457B2203,Novartis Pharmaceuticals,Czech Republic
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,CAIN457B2203,Novartis Pharmaceuticals,France
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,CAIN457B2203,Novartis Pharmaceuticals,Italy
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,CAIN457B2203,Novartis Pharmaceuticals,Japan
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,CAIN457B2203,Novartis Pharmaceuticals,Poland
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,CAIN457B2203,Novartis Pharmaceuticals,Russian Federation
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,CAIN457B2203,Novartis Pharmaceuticals,Spain
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,CAIN457B2203,Novartis Pharmaceuticals,Sweden
760,761,NCT01874340,Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis,CAIN457B2203,Novartis Pharmaceuticals,Turkey
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",215MS201,Biogen,United States
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",215MS201,Biogen,Canada
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",215MS201,Biogen,Czech Republic
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",215MS201,Biogen,France
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",215MS201,Biogen,Hungary
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",215MS201,Biogen,Italy
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",215MS201,Biogen,Netherlands
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",215MS201,Biogen,Poland
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",215MS201,Biogen,Russian Federation
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",215MS201,Biogen,Serbia
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",215MS201,Biogen,Spain
764,765,NCT01864148,"Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",215MS201,Biogen,United Kingdom
765,766,NCT01863888,Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis,LPS13539,Sanofi,Belgium
765,766,NCT01863888,Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis,LPS13539,Sanofi,Germany
765,766,NCT01863888,Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis,LPS13539,Sanofi,Netherlands
767,768,NCT01851434,Natural History of Optic Neuritis,130104,National Institute of Neurological Disorders and Stroke (NINDS),United States
767,768,NCT01851434,Natural History of Optic Neuritis,130104,National Institute of Neurological Disorders and Stroke (NINDS),Israel
770,771,NCT01838824,Applying Speed of Processing Training to Individuals With Multiple Sclerosis,RG 4607-A-3,Kessler Foundation,United States
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Austria
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Belgium
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Canada
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Czech Republic
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Denmark
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Finland
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,France
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Germany
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Hungary
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Israel
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Italy
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Netherlands
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Norway
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Poland
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Portugal
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Slovenia
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Spain
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Sweden
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,Switzerland
785,786,NCT01795872,Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis,16401,Bayer,United Kingdom
790,791,NCT01766063,"Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon",16352,Bayer,Germany
801,802,NCT01718392,"Rehabilitation in Multiple Sclerosis: Influence of Exercise on Development of Insulin Resistance, Muscle Power and Aerobic Capacity",CME 2011/311,Hasselt University,Belgium
805,806,NCT01706055,Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE),16400,Bayer,Poland
813,814,NCT01647880,MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study),MOVING,"Charite University, Berlin, Germany",Germany
821,822,NCT01617395,Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility,120122,National Institute of Neurological Disorders and Stroke (NINDS),United States
828,829,NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,218MS205,Biogen,Belgium
828,829,NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,218MS205,Biogen,Canada
828,829,NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,218MS205,Biogen,Italy
828,829,NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,218MS205,Biogen,Netherlands
828,829,NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,218MS205,Biogen,Sweden
828,829,NCT01597297,Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.,218MS205,Biogen,United Kingdom
833,834,NCT01585298,STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START),CFTY720DDE17,Novartis Pharmaceuticals,Germany
839,840,NCT01556685,"MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia",AVX-MEX-09-17,Biogen,Colombia
839,840,NCT01556685,"MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia",AVX-MEX-09-17,Biogen,Mexico
846,847,NCT01514370,Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a,EMR200136-549,"Merck KGaA, Darmstadt, Germany",Italy
848,849,NCT01500408,Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers,108HV106,Biogen,United States
849,850,NCT01497262,Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,CFTY720D2325,Novartis Pharmaceuticals,Argentina
849,850,NCT01497262,Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,CFTY720D2325,Novartis Pharmaceuticals,Brazil
849,850,NCT01497262,Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,CFTY720D2325,Novartis Pharmaceuticals,Colombia
849,850,NCT01497262,Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,CFTY720D2325,Novartis Pharmaceuticals,Jordan
849,850,NCT01497262,Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,CFTY720D2325,Novartis Pharmaceuticals,Malaysia
849,850,NCT01497262,Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,CFTY720D2325,Novartis Pharmaceuticals,Mexico
849,850,NCT01497262,Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,CFTY720D2325,Novartis Pharmaceuticals,Panama
849,850,NCT01497262,Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,CFTY720D2325,Novartis Pharmaceuticals,Peru
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Albania
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Algeria
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Argentina
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Belgium
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Czechia
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Egypt
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,France
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Germany
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Greece
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Hungary
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Israel
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Kazakhstan
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Netherlands
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Portugal
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Saudi Arabia
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Tunisia
851,852,NCT01491100,Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis,16036,Bayer,Turkey
852,853,NCT01489748,Canadian Avonex PEN Productivity Study,CAN-AVX-11-10239,Biogen,Canada
854,855,NCT01487096,Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,HMR1726D/2001,Sanofi,Canada
854,855,NCT01487096,Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,HMR1726D/2001,Sanofi,France
855,856,NCT01480076,Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis,218MS403,Biogen,Australia
855,856,NCT01480076,Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis,218MS403,Biogen,Belgium
855,856,NCT01480076,Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis,218MS403,Biogen,Denmark
855,856,NCT01480076,Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis,218MS403,Biogen,France
855,856,NCT01480076,Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis,218MS403,Biogen,Germany
855,856,NCT01480076,Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis,218MS403,Biogen,Italy
855,856,NCT01480076,Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis,218MS403,Biogen,Netherlands
855,856,NCT01480076,Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis,218MS403,Biogen,Portugal
855,856,NCT01480076,Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis,218MS403,Biogen,United Kingdom
856,857,NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,218MS401,Biogen,Argentina
856,857,NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,218MS401,Biogen,Canada
856,857,NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,218MS401,Biogen,Czechia
856,857,NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,218MS401,Biogen,France
856,857,NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,218MS401,Biogen,Germany
856,857,NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,218MS401,Biogen,Ireland
856,857,NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,218MS401,Biogen,Israel
856,857,NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,218MS401,Biogen,Lebanon
856,857,NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,218MS401,Biogen,Netherlands
856,857,NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,218MS401,Biogen,Norway
856,857,NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,218MS401,Biogen,Portugal
856,857,NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,218MS401,Biogen,Spain
856,857,NCT01480063,An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice,218MS401,Biogen,United Arab Emirates
866,867,NCT01442194,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,CFTY720D2403,Novartis Pharmaceuticals,United States
866,867,NCT01442194,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,CFTY720D2403,Novartis Pharmaceuticals,Argentina
866,867,NCT01442194,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,CFTY720D2403,Novartis Pharmaceuticals,Australia
866,867,NCT01442194,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,CFTY720D2403,Novartis Pharmaceuticals,Canada
866,867,NCT01442194,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,CFTY720D2403,Novartis Pharmaceuticals,Chile
866,867,NCT01442194,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,CFTY720D2403,Novartis Pharmaceuticals,Mexico
866,867,NCT01442194,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,CFTY720D2403,Novartis Pharmaceuticals,Puerto Rico
867,868,NCT01440101,"Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)",101MS203,Biogen,Japan
868,869,NCT01440062,Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS),EVIDIMS,"Charite University, Berlin, Germany",Germany
870,871,NCT01433250,"A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis",CAIN457B2201E1,Novartis Pharmaceuticals,Czech Republic
870,871,NCT01433250,"A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis",CAIN457B2201E1,Novartis Pharmaceuticals,Russian Federation
870,871,NCT01433250,"A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis",CAIN457B2201E1,Novartis Pharmaceuticals,Ukraine
876,877,NCT01413243,Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome,TRIOMS-01,"Charite University, Berlin, Germany",Germany
878,879,NCT01405872,"Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.",108MS402,Biogen,Denmark
878,879,NCT01405872,"Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.",108MS402,Biogen,France
878,879,NCT01405872,"Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.",108MS402,Biogen,Germany
878,879,NCT01405872,"Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.",108MS402,Biogen,Netherlands
878,879,NCT01405872,"Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.",108MS402,Biogen,Norway
878,879,NCT01405872,"Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.",108MS402,Biogen,Portugal
878,879,NCT01405872,"Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.",108MS402,Biogen,Slovakia
878,879,NCT01405872,"Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.",108MS402,Biogen,Sweden
878,879,NCT01405872,"Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.",108MS402,Biogen,Switzerland
878,879,NCT01405872,"Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.",108MS402,Biogen,United Kingdom
879,880,NCT01403376,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide,PDY11684,Sanofi,Austria
879,880,NCT01403376,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide,PDY11684,Sanofi,Canada
879,880,NCT01403376,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide,PDY11684,Sanofi,Germany
879,880,NCT01403376,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide,PDY11684,Sanofi,Russian Federation
879,880,NCT01403376,Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide,PDY11684,Sanofi,Ukraine
887,888,NCT01366040,Avonex PEN Satisfaction and Patients Experience Clinical Trial,AVX-CAN-11-08,Biogen,Canada
890,891,NCT01354665,Depression and Fatigue in MS Patients Treated With Betaferon.,15307,Bayer,Poland
894,895,NCT01335633,Psychometric Validation of Cognitive Endpoints,691-11 PVCE,Kessler Foundation,United States
895,896,NCT01333501,Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms,CFTY720DIT01,Novartis Pharmaceuticals,Germany
895,896,NCT01333501,Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms,CFTY720DIT01,Novartis Pharmaceuticals,Italy
899,900,NCT01326715,Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis,110116,National Institute of Neurological Disorders and Stroke (NINDS),United States
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,United States
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Argentina
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Australia
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Austria
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Belgium
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Brazil
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Canada
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Colombia
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Cyprus
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Czechia
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Denmark
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Finland
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,France
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Germany
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Greece
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Hungary
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Ireland
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Israel
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Italy
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Lebanon
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Mexico
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Netherlands
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Norway
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Poland
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Portugal
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Romania
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Russian Federation
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Saudi Arabia
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Slovakia
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Slovenia
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Spain
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Sweden
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,Switzerland
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,United Arab Emirates
903,904,NCT01285479,The Gilenya Pregnancy Registry,CFTY720D2404,Novartis Pharmaceuticals,United Kingdom
905,906,NCT01280539,The Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Multiple Sclerosis,MECU2012-002,Hasselt University,Belgium
906,907,NCT01279655,Motor Training and White Matter in Multiple Sclerosis (MS),MECU2012-001,Hasselt University,Belgium
907,908,NCT01272596,Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis,Sloan-Study,"Charite University, Berlin, Germany",Germany
908,909,NCT01272128,Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study,BE-AVO-01,Biogen,Belgium
912,913,NCT01235221,Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.,218MS301,Biogen,Canada
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),ONO-4641POU007 (EMR200559-002),EMD Serono,United States
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),ONO-4641POU007 (EMR200559-002),EMD Serono,Belgium
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),ONO-4641POU007 (EMR200559-002),EMD Serono,Canada
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),ONO-4641POU007 (EMR200559-002),EMD Serono,Czech Republic
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),ONO-4641POU007 (EMR200559-002),EMD Serono,Germany
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),ONO-4641POU007 (EMR200559-002),EMD Serono,Greece
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),ONO-4641POU007 (EMR200559-002),EMD Serono,Japan
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),ONO-4641POU007 (EMR200559-002),EMD Serono,Poland
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),ONO-4641POU007 (EMR200559-002),EMD Serono,Russian Federation
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),ONO-4641POU007 (EMR200559-002),EMD Serono,Spain
914,915,NCT01226745,Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS),ONO-4641POU007 (EMR200559-002),EMD Serono,Ukraine
915,916,NCT01226654,Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis,9812,NYU Langone Health,United States
919,920,NCT01212094,Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe),100212,National Institute of Neurological Disorders and Stroke (NINDS),United States
920,921,NCT01207648,Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY),EMR 200136-024,EMD Serono,United States
920,921,NCT01207648,Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY),EMR 200136-024,EMD Serono,Argentina
920,921,NCT01207648,Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY),EMR 200136-024,EMD Serono,Canada
920,921,NCT01207648,Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY),EMR 200136-024,EMD Serono,France
920,921,NCT01207648,Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY),EMR 200136-024,EMD Serono,Italy
920,921,NCT01207648,Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY),EMR 200136-024,EMD Serono,Russian Federation
920,921,NCT01207648,Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY),EMR 200136-024,EMD Serono,Tunisia
920,921,NCT01207648,Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY),EMR 200136-024,EMD Serono,Venezuela
925,926,NCT01198132,A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly,701068-524,"Merck KGaA, Darmstadt, Germany",France
929,930,NCT01184833,Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis,14323,Bayer,Poland
930,931,NCT01181115,Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS),108MS301,Biogen,China
933,934,NCT01156298,Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance,004-09-AVX,Biogen,United States
936,937,NCT01142557,An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis,REBIJECT II,"Merck KGaA, Darmstadt, Germany",Germany
939,940,NCT01112657,An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period,EMR200077-504,"Merck KGaA, Darmstadt, Germany",Taiwan
940,941,NCT01106365,Repetitive Deep Transcranial Magnetic Stimulation in Multiple Sclerosis,rTMS in MS,"Charite University, Berlin, Germany",Germany
942,943,NCT01101776,Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.,701068-522,"Merck KGaA, Darmstadt, Germany",Australia
947,948,NCT01085318,Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial,29665,EMD Serono,United States
948,949,NCT01084798,A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years,EMR 200077-503,"Merck KGaA, Darmstadt, Germany",Taiwan
951,952,NCT01080573,Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis,MMFM 100,"Merck KGaA, Darmstadt, Germany",United Kingdom
952,953,NCT01080014,Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina,EMR 200077_502,"Merck KGaA, Darmstadt, Germany",Argentina
953,954,NCT01079975,To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis,EMR 200077- 500,"Merck KGaA, Darmstadt, Germany",Argentina
954,955,NCT01076595,"Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period",15098,Bayer,France
955,956,NCT01075737,An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers,200077-501,"Merck KGaA, Darmstadt, Germany",Argentina
958,959,NCT01074346,Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis,EMR 701068-511,"Merck KGaA, Darmstadt, Germany","Korea, Republic of"
960,961,NCT01070823,JC-Virus (JCV) Antibody Program,101JC401,Biogen,United States
965,966,NCT01036165,"A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study",29652,EMD Serono,United States
966,967,NCT01034644,Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15),EMR200136_022,"Merck KGaA, Darmstadt, Germany",Switzerland
967,968,NCT01031459,Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.,14261,Bayer,United States
967,968,NCT01031459,Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.,14261,Bayer,Canada
972,973,NCT01013350,Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials,EMR700568-012,EMD Serono,United States
980,981,NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,14438,Bayer,Austria
980,981,NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,14438,Bayer,Belgium
980,981,NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,14438,Bayer,Finland
980,981,NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,14438,Bayer,Germany
980,981,NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,14438,Bayer,Israel
980,981,NCT00963833,Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis,14438,Bayer,United Kingdom
981,982,NCT00958009,"The Multicenter, Open-label, Single-use Autoinjector Convenience Study",29651,EMD Serono,United States
991,992,NCT00928967,"Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients",14168,Bayer,France
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,EFC10891,Sanofi,Belgium
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,EFC10891,Sanofi,Canada
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,EFC10891,Sanofi,Czech Republic
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,EFC10891,Sanofi,France
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,EFC10891,Sanofi,Germany
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,EFC10891,Sanofi,Greece
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,EFC10891,Sanofi,Hungary
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,EFC10891,Sanofi,Italy
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,EFC10891,Sanofi,Poland
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,EFC10891,Sanofi,Spain
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,EFC10891,Sanofi,Switzerland
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,EFC10891,Sanofi,Tunisia
0,1001,NCT00883337,A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis,EFC10891,Sanofi,United Kingdom
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Australia
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Austria
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Bahrain
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Belgium
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Canada
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Colombia
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Czech Republic
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Denmark
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Egypt
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,France
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Germany
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Greece
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Indonesia
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Israel
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Italy
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Jordan
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Kazakhstan
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,"Korea, Republic of"
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Kuwait
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Lebanon
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Mexico
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Netherlands
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Norway
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Oman
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Portugal
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Slovenia
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Spain
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Sweden
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Switzerland
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Taiwan
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,Thailand
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,United Arab Emirates
1,1002,NCT00882453,Physical Activity and Fatigue in Early Multiple Sclerosis (MS),13853,Bayer,United Kingdom
2,1003,NCT00873340,Physical Disability in Patients Treated With Betaferon,14173,Bayer,Colombia
7,1008,NCT00828204,Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects,108MS302,Biogen,United States
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",DRI10566,Sanofi,United States
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",DRI10566,Sanofi,Canada
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",DRI10566,Sanofi,Finland
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",DRI10566,Sanofi,France
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",DRI10566,Sanofi,Germany
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",DRI10566,Sanofi,Norway
12,1013,NCT00811902,"Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",DRI10566,Sanofi,Spain
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,LTS6047,Sanofi,United States
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,LTS6047,Sanofi,Austria
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,LTS6047,Sanofi,Canada
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,LTS6047,Sanofi,Germany
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,LTS6047,Sanofi,Italy
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,LTS6047,Sanofi,Spain
13,1014,NCT00811395,Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis,LTS6047,Sanofi,United Kingdom
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,United States
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Austria
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Canada
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Chile
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Czech Republic
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Denmark
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Estonia
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Finland
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,France
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Germany
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Italy
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Netherlands
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Norway
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Poland
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Portugal
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Russian Federation
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Sweden
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Switzerland
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Turkey
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,Ukraine
14,1015,NCT00803049,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,LTS6050,Sanofi,United Kingdom
16,1017,NCT00784836,Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients,108MS303,Biogen,United States
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,United States
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Australia
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Austria
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Belarus
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Belgium
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Canada
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Chile
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,China
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Czech Republic
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Estonia
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,France
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Germany
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Greece
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Mexico
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Netherlands
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Philippines
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Poland
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Romania
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Slovakia
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Spain
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Sweden
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Thailand
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Tunisia
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Turkey
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,Ukraine
25,1026,NCT00751881,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,EFC10531,Sanofi,United Kingdom
26,1027,NCT00744679,A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State,101MS406,Biogen,United States
27,1028,NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,28733,EMD Serono,United States
27,1028,NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,28733,EMD Serono,Canada
27,1028,NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,28733,EMD Serono,Germany
27,1028,NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,28733,EMD Serono,Italy
27,1028,NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,28733,EMD Serono,Spain
27,1028,NCT00735007,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,28733,EMD Serono,Sweden
31,1032,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",27904,EMD Serono,United States
31,1032,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",27904,EMD Serono,Argentina
31,1032,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",27904,EMD Serono,Australia
31,1032,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",27904,EMD Serono,Austria
31,1032,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",27904,EMD Serono,France
31,1032,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",27904,EMD Serono,Germany
31,1032,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",27904,EMD Serono,Israel
31,1032,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",27904,EMD Serono,Italy
31,1032,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",27904,EMD Serono,Norway
31,1032,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",27904,EMD Serono,Spain
31,1032,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",27904,EMD Serono,Turkey
31,1032,NCT00702065,"A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment",27904,EMD Serono,United Kingdom
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,United States
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Australia
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Austria
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Bulgaria
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Canada
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Chile
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Czech Republic
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Denmark
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Estonia
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Finland
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,France
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Germany
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Hungary
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Lithuania
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Mexico
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Poland
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Romania
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Russian Federation
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Turkey
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,Ukraine
49,1050,NCT00622700,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,EFC6260,Sanofi,United Kingdom
51,1052,NCT00618267,"ATP Expression in Lymphocytes of MS Patients by Means of ""ImmuKnow®"" Assay.",014-07-NAT,Biogen,United States
55,1056,NCT00599274,Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis,C-862,Biogen,United States
55,1056,NCT00599274,Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis,C-862,Biogen,Australia
55,1056,NCT00599274,Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis,C-862,Biogen,Austria
55,1056,NCT00599274,Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis,C-862,Biogen,Canada
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Austria
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Belgium
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Canada
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Czech Republic
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Denmark
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Finland
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,France
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Germany
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Hungary
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Israel
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Italy
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Netherlands
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Norway
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Poland
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Slovenia
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Spain
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Sweden
58,1059,NCT00544037,BENEFIT Extension Study,91713,Bayer,Switzerland
60,1061,NCT00536120,The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis,101MS404,Biogen,United States
61,1062,NCT00525343,Avonex 15 Year Long Term Follow-up Study,007-06-AVX,Biogen,United States
62,1063,NCT00516893,Natalizumab High Titer Immunogenicity and Safety,101MS201,Biogen,United States
70,1071,NCT00493077,Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy,SAFE,Biogen,Sweden
71,1072,NCT00492765,Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis,SIMCOMBIN,Biogen,Denmark
72,1073,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,PDY6045,Sanofi,United States
72,1073,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,PDY6045,Sanofi,Canada
72,1073,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,PDY6045,Sanofi,Germany
72,1073,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,PDY6045,Sanofi,Italy
72,1073,NCT00489489,Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,PDY6045,Sanofi,Spain
75,1076,NCT00483847,TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World,101MS403,Biogen,Germany
77,1078,NCT00477113,TYSABRI Global Observational Program in Safety,101MS402,Biogen,United States
78,1079,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,PDY6046,Sanofi,United States
78,1079,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,PDY6046,Sanofi,Austria
78,1079,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,PDY6046,Sanofi,Canada
78,1079,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,PDY6046,Sanofi,Germany
78,1079,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,PDY6046,Sanofi,Italy
78,1079,NCT00475865,Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,PDY6046,Sanofi,United Kingdom
82,1083,NCT00464074,Evaluation of Natalizumab for thE Relief of MS Associated FatiGue,001-06-NAT,Biogen,United States
82,1083,NCT00464074,Evaluation of Natalizumab for thE Relief of MS Associated FatiGue,001-06-NAT,Biogen,Puerto Rico
87,1088,NCT00432900,Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis,070092,National Institute of Neurological Disorders and Stroke (NINDS),United States
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Argentina
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Australia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Austria
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Belgium
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Bulgaria
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Canada
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Croatia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Czech Republic
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Estonia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Finland
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",France
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Germany
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Greece
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Israel
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Italy
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Latvia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Lebanon
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Morocco
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Poland
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Portugal
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Romania
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Russian Federation
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Saudi Arabia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Serbia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Slovakia
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Spain
94,1095,NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),IMP27025,"Merck KGaA, Darmstadt, Germany",Turkey
97,1098,NCT00393588,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,070014,National Institute of Neurological Disorders and Stroke (NINDS),United States
101,1102,NCT00370071,"Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis",91386,Bayer,China
105,1106,NCT00342134,Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis,999902196,National Institute of Neurological Disorders and Stroke (NINDS),United States
107,1108,NCT00338741,Rebif® Pregnancy Registry,23888,EMD Serono,United States
112,1113,NCT00325988,Biomarkers in Multiple Sclerosis,050063,National Institute of Neurological Disorders and Stroke (NINDS),United States
115,1116,NCT00321568,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,060154,National Institute of Neurological Disorders and Stroke (NINDS),United States
116,1117,NCT00313976,"Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)",91449,Bayer,Denmark
116,1117,NCT00313976,"Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)",91449,Bayer,Sweden
120,1121,NCT00288990,A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis,008-05-AVX,Biogen,United States
122,1123,NCT00276172,Open-Label Natalizumab Safety Extension Study,C-1808,Biogen,United States
125,1126,NCT00267319,FOCUS Fatigue Outcome in Copaxone USers,HMR4002A_4002,Sanofi,Czech Republic
126,1127,NCT00262314,"Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients",24293,EMD Serono,United States
137,1138,NCT00228163,Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,LTS6048,Sanofi,Canada
137,1138,NCT00228163,Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses,LTS6048,Sanofi,France
144,1145,NCT00206635,Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis,308272,Bayer,United States
144,1145,NCT00206635,Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis,308272,Bayer,Canada
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Austria
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Belgium
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Canada
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Czech Republic
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Denmark
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Finland
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,France
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Germany
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Hungary
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Israel
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Italy
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Netherlands
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Norway
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Poland
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Portugal
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Slovenia
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Spain
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Sweden
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,Switzerland
150,1151,NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,91031,Bayer,United Kingdom
152,1153,NCT00168701,Efficacy and Safety of BG00012 in MS,C-1900,Biogen,Czech Republic
152,1153,NCT00168701,Efficacy and Safety of BG00012 in MS,C-1900,Biogen,Germany
152,1153,NCT00168701,Efficacy and Safety of BG00012 in MS,C-1900,Biogen,Hungary
152,1153,NCT00168701,Efficacy and Safety of BG00012 in MS,C-1900,Biogen,Netherlands
152,1153,NCT00168701,Efficacy and Safety of BG00012 in MS,C-1900,Biogen,Poland
152,1153,NCT00168701,Efficacy and Safety of BG00012 in MS,C-1900,Biogen,Russian Federation
152,1153,NCT00168701,Efficacy and Safety of BG00012 in MS,C-1900,Biogen,Sweden
152,1153,NCT00168701,Efficacy and Safety of BG00012 in MS,C-1900,Biogen,Switzerland
152,1153,NCT00168701,Efficacy and Safety of BG00012 in MS,C-1900,Biogen,Turkey
152,1153,NCT00168701,Efficacy and Safety of BG00012 in MS,C-1900,Biogen,United Kingdom
153,1154,NCT00166283,Improving New Learning and Memory in Multiple Sclerosis,ndcnih2004,Kessler Foundation,United States
158,1159,NCT00142402,Modafinil in Multiple Sclerosis,ndcnmss2004,Kessler Foundation,United States
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,United States
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Austria
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Canada
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Chile
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Czech Republic
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Denmark
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Estonia
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Finland
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,France
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Germany
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Italy
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Netherlands
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Norway
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Poland
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Portugal
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Russian Federation
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Sweden
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Switzerland
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Turkey
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,Ukraine
162,1163,NCT00134563,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,EFC6049,Sanofi,United Kingdom
166,1167,NCT00110396,Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis,25632,EMD Serono,United States
168,1169,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,NN18344,Hoffmann-La Roche,Bulgaria
168,1169,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,NN18344,Hoffmann-La Roche,Canada
168,1169,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,NN18344,Hoffmann-La Roche,Czech Republic
168,1169,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,NN18344,Hoffmann-La Roche,Germany
168,1169,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,NN18344,Hoffmann-La Roche,Poland
168,1169,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,NN18344,Hoffmann-La Roche,Russian Federation
168,1169,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,NN18344,Hoffmann-La Roche,Slovakia
168,1169,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,NN18344,Hoffmann-La Roche,Spain
168,1169,NCT00104143,A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.,NN18344,Hoffmann-La Roche,United Kingdom
170,1171,NCT00099307,Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis,050039,National Institute of Neurological Disorders and Stroke (NINDS),United States
188,1189,NCT00011375,Rolipram to Treat Multiple Sclerosis,010089,National Institute of Neurological Disorders and Stroke (NINDS),United States
195,1196,NCT00001934,Zenapax to Treat Multiple Sclerosis,990169,National Institute of Neurological Disorders and Stroke (NINDS),United States
196,1197,NCT00001781,"Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)",980069,National Institute of Neurological Disorders and Stroke (NINDS),United States
197,1198,NCT00001669,A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients,970148,National Institute of Neurological Disorders and Stroke (NINDS),United States
198,1199,NCT00001248,Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS),890045,National Institute of Neurological Disorders and Stroke (NINDS),United States
199,1200,NCT04856384,Effect of Variance on Error Correction During Coupling,MS-Music-LM-001,Hasselt University,Belgium
204,1205,NCT04756687,Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera,FR-BGT-11758,Biogen,France
205,1206,NCT04655222,Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program,DE-PEG-11650,Biogen,Germany
211,1212,NCT01143441,Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS),100125,National Institute of Neurological Disorders and Stroke (NINDS),United States
212,1213,NCT00461396,"Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron",14465,Bayer,United States
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,109MS310,Biogen,United States
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,109MS310,Biogen,Belgium
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,109MS310,Biogen,Bulgaria
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,109MS310,Biogen,Kuwait
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,109MS310,Biogen,Lithuania
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,109MS310,Biogen,Poland
220,1221,NCT02525874,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,109MS310,Biogen,Turkey
221,1222,NCT02423083,Oral Guanabenz for Multiple Sclerosis,150117,National Institute of Neurological Disorders and Stroke (NINDS),United States
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,109MS408,Biogen,Austria
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,109MS408,Biogen,Belgium
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,109MS408,Biogen,Canada
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,109MS408,Biogen,Czechia
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,109MS408,Biogen,France
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,109MS408,Biogen,Hungary
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,109MS408,Biogen,Italy
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,109MS408,Biogen,Portugal
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,109MS408,Biogen,Slovakia
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,109MS408,Biogen,Slovenia
224,1225,NCT01930708,A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes,109MS408,Biogen,Spain
225,1226,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS305,Biogen,Czechia
225,1226,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS305,Biogen,Japan
225,1226,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS305,Biogen,"Korea, Republic of"
225,1226,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS305,Biogen,Poland
225,1226,NCT01838668,An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS305,Biogen,Taiwan
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,United States
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Argentina
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Australia
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Brazil
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Canada
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Czechia
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Denmark
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,France
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Georgia
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Germany
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Greece
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Hungary
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,India
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Ireland
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Israel
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Italy
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Mexico
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,"Moldova, Republic of"
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Poland
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Romania
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Russian Federation
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Serbia
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Spain
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Sweden
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Switzerland
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,Ukraine
226,1227,NCT01797965,Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019,205MS303,Biogen,United Kingdom
227,1228,NCT01416155,Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis,101MS204,Biogen,Japan
228,1229,NCT01244139,Safety Study of BIIB033 in Subjects With Multiple Sclerosis,215MS101,Biogen,United States
229,1230,NCT01156311,BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis,109MS201,Biogen,United States
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,United States
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Argentina
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Australia
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Austria
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Belgium
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Brazil
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Canada
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Chile
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Colombia
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Denmark
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Estonia
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Finland
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,France
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Germany
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Greece
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Hungary
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Italy
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,"Korea, Republic of"
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Lithuania
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Netherlands
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Norway
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Portugal
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Russian Federation
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Slovakia
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Spain
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Sweden
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,Tunisia
236,1237,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,EFC6058,Sanofi,United Kingdom
241,1242,NCT04847596,A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,COMB157GUS18,Novartis Pharmaceuticals,United States
243,1244,NCT04667117,A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,COMB157GUS12,Novartis Pharmaceuticals,United States
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,United States
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,Austria
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,Brazil
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,Bulgaria
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,Canada
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,Denmark
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,France
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,Greece
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,Italy
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,"Korea, Republic of"
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,Mexico
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,Poland
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,Russian Federation
246,1247,NCT04586023,Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN42272,Hoffmann-La Roche,Turkey
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN41851,Hoffmann-La Roche,United States
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN41851,Hoffmann-La Roche,Argentina
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN41851,Hoffmann-La Roche,Finland
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN41851,Hoffmann-La Roche,Germany
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN41851,Hoffmann-La Roche,Hong Kong
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN41851,Hoffmann-La Roche,Italy
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN41851,Hoffmann-La Roche,Peru
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN41851,Hoffmann-La Roche,Portugal
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN41851,Hoffmann-La Roche,Russian Federation
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN41851,Hoffmann-La Roche,Spain
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN41851,Hoffmann-La Roche,Taiwan
247,1248,NCT04586010,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS),GN41851,Hoffmann-La Roche,Ukraine
249,1250,NCT04486716,"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis",COMB157GUS07,Novartis Pharmaceuticals,United States
249,1250,NCT04486716,"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis",COMB157GUS07,Novartis Pharmaceuticals,Puerto Rico
250,1251,NCT04441229,Mobile Attentional Bias Modification Training in Pediatric MS,19-00810,NYU Langone Health,United States
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,United States
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Argentina
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Belgium
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Brazil
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Canada
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Chile
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Croatia
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Czechia
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,France
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Germany
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Greece
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Hungary
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,India
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Israel
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,"Korea, Republic of"
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Latvia
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Netherlands
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Norway
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Portugal
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Puerto Rico
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Russian Federation
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Serbia
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Slovakia
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Spain
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Turkey
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,Ukraine
251,1252,NCT04410991,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16034,Sanofi,United Kingdom
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,United States
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Belarus
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Bulgaria
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Canada
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,China
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Czechia
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Denmark
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Estonia
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Finland
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Germany
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Italy
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Japan
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Lithuania
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Poland
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Romania
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Russian Federation
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Spain
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Sweden
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Taiwan
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Turkey
252,1253,NCT04410978,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16033,Sanofi,Ukraine
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,United States
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Australia
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Austria
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Belgium
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Bulgaria
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Canada
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Czechia
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Germany
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Greece
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Hungary
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Italy
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Lebanon
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Mexico
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Norway
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Poland
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Portugal
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Russian Federation
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Saudi Arabia
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Slovakia
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Spain
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Switzerland
254,1255,NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,COMB157G23101,Novartis Pharmaceuticals,Turkey
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,LTS16004,Sanofi,United States
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,LTS16004,Sanofi,Canada
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,LTS16004,Sanofi,Czechia
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,LTS16004,Sanofi,Estonia
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,LTS16004,Sanofi,France
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,LTS16004,Sanofi,Netherlands
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,LTS16004,Sanofi,Russian Federation
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,LTS16004,Sanofi,Spain
259,1260,NCT03996291,Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis,LTS16004,Sanofi,Ukraine
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,DRI15928,Sanofi,United States
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,DRI15928,Sanofi,Canada
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,DRI15928,Sanofi,Czechia
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,DRI15928,Sanofi,Estonia
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,DRI15928,Sanofi,France
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,DRI15928,Sanofi,Netherlands
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,DRI15928,Sanofi,Russian Federation
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,DRI15928,Sanofi,Slovakia
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,DRI15928,Sanofi,Spain
260,1261,NCT03889639,Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis,DRI15928,Sanofi,Ukraine
261,1262,NCT03856619,To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis,TERIFL08918,Sanofi,India
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,United States
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Argentina
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Australia
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Austria
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Belgium
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Bulgaria
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Canada
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Croatia
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Czechia
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Denmark
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Estonia
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Finland
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,France
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Germany
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Greece
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Hungary
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,India
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Israel
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Japan
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Latvia
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Lithuania
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Mexico
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Netherlands
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Norway
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Peru
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Poland
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Portugal
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Russian Federation
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Slovakia
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,South Africa
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Spain
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Sweden
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Switzerland
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Taiwan
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Thailand
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,Turkey
262,1263,NCT03650114,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",COMB157G2399,Novartis Pharmaceuticals,United Kingdom
263,1264,NCT03257358,A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod,CFTY720DUS40,Novartis Pharmaceuticals,United States
264,1265,NCT03249714,Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab,COMB157G1301,Novartis Pharmaceuticals,Japan
264,1265,NCT03249714,Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab,COMB157G1301,Novartis Pharmaceuticals,Russian Federation
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,United States
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Argentina
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Australia
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Belgium
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Bulgaria
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Canada
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Croatia
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Czechia
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Denmark
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Estonia
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,France
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Germany
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Greece
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Hungary
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,India
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Israel
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Italy
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Mexico
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Netherlands
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Poland
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Puerto Rico
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Russian Federation
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Slovakia
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Spain
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Sweden
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Switzerland
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Thailand
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,Turkey
268,1269,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,COMB157G2301,Novartis Pharmaceuticals,United Kingdom
269,1270,NCT02241785,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies,101MS409,Biogen,United States
271,1272,NCT02142192,Natalizumab Subcutaneous Immunogenicity and Safety Study,101MS207,Biogen,Belgium
273,1274,NCT01939002,Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017),105MS303,Biogen,United States
275,1276,NCT01601119,Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients,EMR200136_550,"Merck KGaA, Darmstadt, Germany",United Kingdom
276,1277,NCT01601080,"An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device",EMR200077-516,"Merck KGaA, Darmstadt, Germany",United Kingdom
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,United States
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Argentina
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Belarus
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Belgium
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Bosnia and Herzegovina
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Brazil
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Bulgaria
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Canada
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Croatia
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Czechia
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,France
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Germany
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Ireland
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Italy
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Mexico
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Norway
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Poland
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Russian Federation
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Slovakia
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Spain
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Sweden
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Turkey
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,Ukraine
277,1278,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21093,Hoffmann-La Roche,United Kingdom
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,United States
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Belgium
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Bulgaria
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Canada
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Chile
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Colombia
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Croatia
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Czech Republic
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Estonia
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,France
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Georgia
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Germany
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Greece
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,India
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Latvia
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Mexico
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Netherlands
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,New Zealand
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Peru
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Poland
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Romania
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Russian Federation
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Serbia
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Spain
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,Ukraine
280,1281,NCT01332019,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,105MS302,Biogen,United Kingdom
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,United States
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Argentina
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Australia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Austria
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Belgium
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Brazil
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Bulgaria
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Chile
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Czechia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Estonia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Finland
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,France
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Germany
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Hungary
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Israel
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Italy
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Latvia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Lithuania
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Mexico
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Netherlands
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Peru
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Poland
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Portugal
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Russian Federation
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Serbia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Slovakia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,South Africa
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Spain
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Switzerland
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Tunisia
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,Ukraine
281,1282,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,WA21092,Hoffmann-La Roche,United Kingdom
284,1285,NCT01070836,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,101JC402,Biogen,United States
284,1285,NCT01070836,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,101JC402,Biogen,Puerto Rico
286,1287,NCT01034579,The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial,EMR200136_023,EMD Serono,United States
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,United States
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Belgium
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Bulgaria
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Canada
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Chile
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Colombia
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Croatia
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Czech Republic
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Estonia
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,France
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Georgia
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Germany
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Greece
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,India
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Latvia
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Mexico
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Netherlands
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,New Zealand
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Peru
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Poland
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Romania
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Russian Federation
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Serbia
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Spain
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,Ukraine
289,1290,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,105MS301,Biogen,United Kingdom
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,United States
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,Australia
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,Belgium
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,Canada
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,Czech Republic
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,France
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,Germany
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,Lebanon
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,Lithuania
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,Netherlands
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,New Caledonia
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,Russian Federation
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,Spain
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,Sweden
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,Switzerland
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,Ukraine
290,1291,NCT00853762,"Atacicept in Multiple Sclerosis Extension Study, Phase II",28851,EMD Serono,United Kingdom
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,United States
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Australia
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Austria
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Belgium
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Canada
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Czech Republic
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,France
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Germany
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Lebanon
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Lithuania
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Netherlands
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Russian Federation
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Spain
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Sweden
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Switzerland
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,Ukraine
292,1293,NCT00642902,A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS),28063,EMD Serono,United Kingdom
293,1294,NCT00619307,Transition to Rebif New Formulation,27571,"Merck KGaA, Darmstadt, Germany",France
293,1294,NCT00619307,Transition to Rebif New Formulation,27571,"Merck KGaA, Darmstadt, Germany",Germany
294,1295,NCT00472797,Rebif New Formulation (RNF) Quality of Life (QOL) Study,27955,EMD Serono,United States
299,1300,NCT03423121,A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis,IRB00144766,Johns Hopkins University,United States
302,1303,NCT02977533,A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis,TDU14981,Sanofi,Germany
316,1317,NCT05058729,MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study,US-MSG-11834,Biogen,United States
322,1323,NCT03972306,"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis",CN41144,Hoffmann-La Roche,United States
322,1323,NCT03972306,"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis",CN41144,Hoffmann-La Roche,Canada
337,1338,NCT04982991,Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants,PKM17247,Sanofi,United Kingdom
349,1350,NCT02323269,Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve),109MS415,Biogen,Canada
356,1357,NCT02253264,A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients,IRB00027318,Johns Hopkins University,United States
359,1360,NCT00559702,Safety Study of Natalizumab to Treat Multiple Sclerosis (MS),101MS102,Biogen,United States
363,1364,NCT03185065,"Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis",IRB00119702,Johns Hopkins University,United States
365,1366,NCT01490840,Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis,CFTY720DDE07,Novartis Pharmaceuticals,Germany
368,1369,NCT04940065,Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen,COMB157G1401,Novartis Pharmaceuticals,Japan
371,1372,NCT04885894,An Examination of Cognitive Fatigue Using Functional Neuroimaging,R-1150-21,Kessler Foundation,United States
375,1376,NCT04565431,Examining Effects of Tysabri on Cognitive Fatigue Using fMRI,US-TYS-11640,Kessler Foundation,United States
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,United States
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Argentina
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Australia
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Austria
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Brazil
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Canada
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Denmark
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,France
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Greece
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Hungary
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Israel
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Mexico
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Peru
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Poland
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Portugal
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Puerto Rico
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Russian Federation
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Spain
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Turkey
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,Ukraine
377,1378,NCT04544449,A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis,GN41791,Hoffmann-La Roche,United Kingdom
381,1382,NCT04448977,Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI,R-1104-20,Kessler Foundation,United States
383,1384,NCT04261790,Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis,IRB00230800,Johns Hopkins University,United States
386,1387,NCT04221191,"Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP",FRA-BGT-18-11469,Biogen,France
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,United States
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Australia
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Austria
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Belgium
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Bulgaria
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Canada
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Colombia
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Croatia
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Egypt
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,France
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Georgia
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Germany
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Hungary
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Ireland
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Italy
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Mexico
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,New Zealand
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Poland
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Portugal
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Romania
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Russian Federation
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Serbia
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Spain
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,Ukraine
390,1391,NCT04035005,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis,WA40404,Hoffmann-La Roche,United Kingdom
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,United States
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Argentina
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Australia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Belgium
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Bulgaria
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Croatia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Czechia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,France
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Germany
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Greece
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Hungary
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Israel
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Italy
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Kuwait
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Portugal
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Russian Federation
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Saudi Arabia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Serbia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Slovakia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Spain
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Tunisia
393,1394,NCT03958877,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",105MS306,Biogen,Turkey
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,800MS301,Biogen,United States
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,800MS301,Biogen,Colombia
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,800MS301,Biogen,Estonia
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,800MS301,Biogen,Hungary
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,800MS301,Biogen,Jordan
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,800MS301,Biogen,"Korea, Republic of"
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,800MS301,Biogen,Malaysia
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,800MS301,Biogen,Mexico
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,800MS301,Biogen,Saudi Arabia
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,800MS301,Biogen,Taiwan
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,800MS301,Biogen,Thailand
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,800MS301,Biogen,Tunisia
395,1396,NCT03870763,Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants,800MS301,Biogen,Turkey
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",101MS329,Biogen,United States
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",101MS329,Biogen,Australia
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",101MS329,Biogen,Belgium
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",101MS329,Biogen,Canada
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",101MS329,Biogen,France
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",101MS329,Biogen,Germany
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",101MS329,Biogen,Israel
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",101MS329,Biogen,Italy
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",101MS329,Biogen,Netherlands
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",101MS329,Biogen,Spain
400,1401,NCT03689972,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",101MS329,Biogen,United Kingdom
404,1405,NCT03500328,Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial,IRB00143534,Johns Hopkins University,United States
407,1408,NCT03387046,A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS),MS200136_0041,"Merck KGaA, Darmstadt, Germany",Italy
408,1409,NCT03347370,A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis,GER-PEG-16-10988,Biogen,Germany
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,United States
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Argentina
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Australia
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Austria
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Belgium
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Brazil
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Bulgaria
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Canada
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Croatia
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Denmark
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,France
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Germany
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Hungary
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Italy
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Kuwait
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Lebanon
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Mexico
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Netherlands
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Norway
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Poland
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Portugal
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Romania
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Slovakia
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Slovenia
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Spain
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Sweden
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Switzerland
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,Turkey
415,1416,NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),MA30143,Hoffmann-La Roche,United Kingdom
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Australia
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Belgium
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Czechia
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Denmark
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Estonia
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Finland
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,France
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Germany
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Ireland
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Italy
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Netherlands
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Norway
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Spain
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Sweden
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Switzerland
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,Turkey
419,1420,NCT02861014,A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT),MA30005,Hoffmann-La Roche,United Kingdom
425,1426,NCT02652091,Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction,17942,Bayer,United States
429,1430,NCT02598167,Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition,ML29715,Hoffmann-La Roche,Spain
432,1433,NCT02579681,Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012,ITA-BGT-12-10389,Biogen,Italy
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS311,Biogen,United States
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS311,Biogen,Belgium
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS311,Biogen,Bulgaria
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS311,Biogen,Czechia
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS311,Biogen,Germany
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS311,Biogen,Kuwait
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS311,Biogen,Latvia
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS311,Biogen,Lebanon
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS311,Biogen,Poland
433,1434,NCT02555215,Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS),109MS311,Biogen,Turkey
434,1435,NCT02545868,A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis,BN29739,Hoffmann-La Roche,United States
434,1435,NCT02545868,A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis,BN29739,Hoffmann-La Roche,Canada
438,1439,NCT02471560,Tecfidera and the Gut Microbiota,NOR-BGT-14-10665,Biogen,Norway
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,109MS202,Biogen,United States
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,109MS202,Biogen,Belgium
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,109MS202,Biogen,Bulgaria
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,109MS202,Biogen,Czechia
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,109MS202,Biogen,Germany
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,109MS202,Biogen,Kuwait
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,109MS202,Biogen,Latvia
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,109MS202,Biogen,Lebanon
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,109MS202,Biogen,Poland
443,1444,NCT02410200,Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS,109MS202,Biogen,Turkey
444,1445,NCT02394782,Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL),EMR200136-591,"Merck KGaA, Darmstadt, Germany",Germany
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,17591,Bayer,Austria
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,17591,Bayer,Belgium
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,17591,Bayer,Bosnia and Herzegovina
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,17591,Bayer,Croatia
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,17591,Bayer,Czechia
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,17591,Bayer,France
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,17591,Bayer,Greece
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,17591,Bayer,Hungary
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,17591,Bayer,Italy
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,17591,Bayer,Spain
449,1450,NCT02247310,BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon,17591,Bayer,Switzerland
450,1451,NCT02064816,A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis,200136-570,"Merck KGaA, Darmstadt, Germany",Germany
452,1453,NCT02019550,Rebif® Rebidose® Versus Rebiject II® Ease-of-Use,200136-573,EMD Serono,United States
456,1457,NCT01667796,Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health,NA_00049428,Johns Hopkins University,United States
462,1463,NCT01436838,"China Betaferon Adherence, Coping and Nurse Support Study",15916,Bayer,China
466,1467,NCT01420055,Fingolimod -Response According to Coping - Evaluation,CFTY720DFR03,Novartis Pharmaceuticals,France
467,1468,NCT01417312,Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients,MS_GTE,"Charite University, Berlin, Germany",Germany
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,United States
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Australia
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Austria
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Belgium
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Brazil
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Bulgaria
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Canada
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Czechia
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Finland
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,France
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Germany
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Greece
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Hungary
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Israel
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Italy
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Lithuania
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Mexico
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Netherlands
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,New Zealand
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Norway
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Peru
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Poland
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Portugal
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Romania
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Russian Federation
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Spain
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Switzerland
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Ukraine
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,United Kingdom
472,1473,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,WA25046,Hoffmann-La Roche,Uruguay
474,1475,NCT01158183,Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis,14838,Bayer,United States
478,1479,NCT01134627,Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS],IMP 26588,"Merck KGaA, Darmstadt, Germany",Denmark
480,1481,NCT01112345,An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters,EMR 701068-513,"Merck KGaA, Darmstadt, Germany",Greece
481,1482,NCT01110993,An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF),EMR 701068-516,"Merck KGaA, Darmstadt, Germany",Poland
482,1483,NCT01108887,"An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.",EMR 701068-526,"Merck KGaA, Darmstadt, Germany",Netherlands
483,1484,NCT01080053,"Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)",EMR200077-511,"Merck KGaA, Darmstadt, Germany",Argentina
484,1485,NCT01080040,To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients,EMR200077-507,"Merck KGaA, Darmstadt, Germany",Argentina
485,1486,NCT01080027,"Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)",EMR 701068_506,"Merck KGaA, Darmstadt, Germany",Greece
486,1487,NCT01080001,"A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina",EMR 200077-506,"Merck KGaA, Darmstadt, Germany",Argentina
487,1488,NCT01075880,Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®,EMR 701068-519,"Merck KGaA, Darmstadt, Germany",Czech Republic
488,1489,NCT01071694,QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea,15110,Bayer,"Korea, Republic of"
492,1493,NCT00780455,Rehabilitation Study in MS Patients,13089,Bayer,France
494,1495,NCT00675883,COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS,AVX-CAN-0703,Biogen,Canada
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,United States
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Argentina
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Australia
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Austria
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Belgium
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Brazil
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Canada
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Denmark
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Finland
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,France
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Germany
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Greece
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Hungary
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Ireland
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Israel
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Italy
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Latvia
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Netherlands
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Norway
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Poland
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Russian Federation
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Slovenia
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Spain
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Sweden
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Switzerland
497,1498,NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,91656,Bayer,Ukraine
499,1500,NCT00306592,Natalizumab Re-Initiation of Dosing,101-MS-322,Biogen,United States
499,1500,NCT00306592,Natalizumab Re-Initiation of Dosing,101-MS-322,Biogen,Canada
505,1506,NCT00235989,Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis,91272,Bayer,United States
509,1510,NCT00206648,An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS,91293,Bayer,United States
509,1510,NCT00206648,An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS,91293,Bayer,Canada
510,1511,NCT00112034,"AVONEX® Combination Trial - ""ACT""",C-865,Biogen,United States
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,United States
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Argentina
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Australia
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Austria
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Belgium
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Brazil
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Canada
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Denmark
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Finland
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,France
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Germany
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Greece
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Hungary
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Ireland
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Israel
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Italy
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Latvia
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Netherlands
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Norway
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Poland
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Russian Federation
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Slovenia
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Spain
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Sweden
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Switzerland
511,1512,NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,91162,Bayer,Ukraine
514,1515,NCT00071838,Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis,040019,National Institute of Neurological Disorders and Stroke (NINDS),United States
517,1518,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,C-1802,Biogen,United States
517,1518,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,C-1802,Biogen,Austria
517,1518,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,C-1802,Biogen,Belgium
517,1518,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,C-1802,Biogen,France
517,1518,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,C-1802,Biogen,Germany
517,1518,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,C-1802,Biogen,Israel
517,1518,NCT00030966,Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis,C-1802,Biogen,Italy
518,1519,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,C-1801,Biogen,United States
518,1519,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,C-1801,Biogen,Belgium
518,1519,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,C-1801,Biogen,Canada
518,1519,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,C-1801,Biogen,Czech Republic
518,1519,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,C-1801,Biogen,France
518,1519,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,C-1801,Biogen,Germany
518,1519,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,C-1801,Biogen,Netherlands
518,1519,NCT00027300,Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis,C-1801,Biogen,United Kingdom
525,1526,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,109MS308,Biogen,United States
525,1526,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,109MS308,Biogen,Belgium
525,1526,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,109MS308,Biogen,Czech Republic
525,1526,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,109MS308,Biogen,Netherlands
525,1526,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,109MS308,Biogen,Poland
525,1526,NCT02430532,BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis,109MS308,Biogen,Slovakia
529,1530,NCT02038049,A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis,CVAY736X2202,Novartis Pharmaceuticals,United States
529,1530,NCT02038049,A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis,CVAY736X2202,Novartis Pharmaceuticals,Czechia
529,1530,NCT02038049,A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis,CVAY736X2202,Novartis Pharmaceuticals,Ukraine
539,1540,NCT04832399,Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants,PRT-TYS-12-10409,Biogen,Portugal
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,United States
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Argentina
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Australia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Austria
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Belarus
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Belgium
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Bulgaria
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Canada
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Chile
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,China
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Colombia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Croatia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Czechia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Denmark
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Estonia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,France
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Germany
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Greece
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Hungary
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,India
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Israel
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Italy
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Japan
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Latvia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Netherlands
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Norway
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Poland
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Portugal
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Romania
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Russian Federation
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Serbia
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Spain
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Sweden
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Switzerland
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Turkey
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,Ukraine
545,1546,NCT04458051,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16035,Sanofi,United Kingdom
562,1563,NCT03177083,Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy,PRT-PEG-15-10880,Biogen,Portugal
564,1565,NCT03093324,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,ALK8700-A302,Biogen,United States
564,1565,NCT03093324,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,ALK8700-A302,Biogen,Germany
564,1565,NCT03093324,A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2,ALK8700-A302,Biogen,Poland
565,1566,NCT03091569,Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy,ITA-PEG-15-10859,Biogen,Italy
571,1572,NCT02720107,Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01),CFTY720DDE01E1,Novartis Pharmaceuticals,Germany
574,1575,NCT02677077,Clinical Disease Activity With Long Term Natalizumab Treatment,BEL-TYS-14-10727,Biogen,Belgium
574,1575,NCT02677077,Clinical Disease Activity With Long Term Natalizumab Treatment,BEL-TYS-14-10727,Biogen,Czechia
575,1576,NCT02647502,A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis,IRB00065806,Johns Hopkins University,United States
579,1580,NCT02373098,Fingolimod Effect on Cytokine and Chemokine Levels,CFTY720DTR04,Novartis Pharmaceuticals,Turkey
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,101MS408,Biogen,United States
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,101MS408,Biogen,Australia
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,101MS408,Biogen,Czechia
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,101MS408,Biogen,France
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,101MS408,Biogen,Germany
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,101MS408,Biogen,Italy
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,101MS408,Biogen,Spain
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,101MS408,Biogen,Sweden
581,1582,NCT02342704,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,101MS408,Biogen,United Kingdom
582,1583,NCT02335892,PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod,CFTY720DGB04,Novartis Pharmaceuticals,United Kingdom
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,United States
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Belgium
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Bulgaria
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Canada
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Czechia
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Denmark
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,France
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Germany
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Hungary
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Israel
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Italy
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Kuwait
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Poland
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Serbia
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Spain
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Sweden
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,Turkey
588,1589,NCT02283853,Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS),109MS306,Biogen,United Kingdom
596,1597,NCT02159573,"Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)",109MS412,Biogen,United States
597,1598,NCT02142205,"Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",RUS-TYS-11-10158,Biogen,Russian Federation
598,1599,NCT02125604,Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany,109MS407,Biogen,Germany
600,1601,NCT02090413,Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis,109MS406,Biogen,Ireland
600,1601,NCT02090413,Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis,109MS406,Biogen,United Kingdom
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,United States
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Bulgaria
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Croatia
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Czech Republic
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Finland
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Greece
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Hungary
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Italy
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Mexico
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Poland
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Russian Federation
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Serbia
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,South Africa
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Spain
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Turkey
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,Ukraine
604,1605,NCT01963611,"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)",EMR200575-001,EMD Serono,United Kingdom
606,1607,NCT01943526,Ireland Natalizumab (TYSABRI) Observational Program,TYS-IRL-11-4,Biogen,Ireland
609,1610,NCT01884935,PK and PD Study of Natalizumab in Pediatric Subjects With RRMS,101MS328,Biogen,Italy
611,1612,NCT01808885,Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.,WP29866,Hoffmann-La Roche,France
613,1614,NCT01790269,Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod,NKcells Gilenya®-treated MS,"Charite University, Berlin, Germany",Germany
621,1622,NCT01706107,Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants,CAN-TYS-12-10333,Biogen,Canada
624,1625,NCT01623596,Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.,CFTY720DUS09,Novartis Pharmaceuticals,United States
624,1625,NCT01623596,Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.,CFTY720DUS09,Novartis Pharmaceuticals,Puerto Rico
628,1629,NCT01538355,A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis,IGEL,"Charite University, Berlin, Germany",Germany
629,1630,NCT01534182,Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC),CFTY720DRU01,Novartis Pharmaceuticals,Russian Federation
630,1631,NCT01498887,Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy,CFTY720DES03,Novartis Pharmaceuticals,Australia
630,1631,NCT01498887,Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy,CFTY720DES03,Novartis Pharmaceuticals,Spain
631,1632,NCT01490502,Vitamin D Supplementation in Multiple Sclerosis,NA_00049137,Johns Hopkins University,United States
632,1633,NCT01485003,Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants,101MS407,Biogen,United States
634,1635,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,205MS302,Biogen,United States
634,1635,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,205MS302,Biogen,Czech Republic
634,1635,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,205MS302,Biogen,Hungary
634,1635,NCT01462318,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,205MS302,Biogen,Poland
640,1641,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",101MS206,Biogen,Belgium
640,1641,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",101MS206,Biogen,France
640,1641,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",101MS206,Biogen,Germany
640,1641,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",101MS206,Biogen,Italy
640,1641,NCT01405820,"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",101MS206,Biogen,Spain
642,1643,NCT01317004,Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change,CFTY720DIT02,Novartis Pharmaceuticals,Italy
643,1644,NCT01310166,Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,CFTY720DDE01,Novartis Pharmaceuticals,Germany
645,1646,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,EMR 200136-532,"Merck KGaA, Darmstadt, Germany",Austria
645,1646,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,EMR 200136-532,"Merck KGaA, Darmstadt, Germany",Denmark
645,1646,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,EMR 200136-532,"Merck KGaA, Darmstadt, Germany",Estonia
645,1646,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,EMR 200136-532,"Merck KGaA, Darmstadt, Germany",Finland
645,1646,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,EMR 200136-532,"Merck KGaA, Darmstadt, Germany",Germany
645,1646,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,EMR 200136-532,"Merck KGaA, Darmstadt, Germany",Italy
645,1646,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,EMR 200136-532,"Merck KGaA, Darmstadt, Germany",Latvia
645,1646,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,EMR 200136-532,"Merck KGaA, Darmstadt, Germany",Lithuania
645,1646,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,EMR 200136-532,"Merck KGaA, Darmstadt, Germany",Netherlands
645,1646,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,EMR 200136-532,"Merck KGaA, Darmstadt, Germany",Norway
645,1646,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,EMR 200136-532,"Merck KGaA, Darmstadt, Germany",Portugal
645,1646,NCT01285401,Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment,EMR 200136-532,"Merck KGaA, Darmstadt, Germany",Switzerland
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201E1,Novartis Pharmaceuticals,United States
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201E1,Novartis Pharmaceuticals,Canada
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201E1,Novartis Pharmaceuticals,Finland
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201E1,Novartis Pharmaceuticals,Germany
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201E1,Novartis Pharmaceuticals,Hungary
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201E1,Novartis Pharmaceuticals,Italy
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201E1,Novartis Pharmaceuticals,Norway
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201E1,Novartis Pharmaceuticals,Poland
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201E1,Novartis Pharmaceuticals,Russian Federation
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201E1,Novartis Pharmaceuticals,Spain
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201E1,Novartis Pharmaceuticals,Switzerland
648,1649,NCT01185821,"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201E1,Novartis Pharmaceuticals,Turkey
655,1656,NCT01071083,Treatment Interruption of Natalizumab,101MS205,Biogen,United States
655,1656,NCT01071083,Treatment Interruption of Natalizumab,101MS205,Biogen,Germany
655,1656,NCT01071083,Treatment Interruption of Natalizumab,101MS205,Biogen,Spain
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,United States
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Argentina
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Australia
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Brazil
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Canada
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Czech Republic
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Denmark
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Finland
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,France
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Georgia
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Germany
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Greece
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Hungary
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,India
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Ireland
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Israel
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Italy
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Mexico
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,"Moldova, Republic of"
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Poland
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Romania
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Russian Federation
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Serbia
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Spain
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Sweden
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Switzerland
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,Ukraine
657,1658,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,205MS301,Biogen,United Kingdom
658,1659,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",101MS325,Biogen,United States
658,1659,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",101MS325,Biogen,Australia
658,1659,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",101MS325,Biogen,Canada
658,1659,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",101MS325,Biogen,Czech Republic
658,1659,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",101MS325,Biogen,Finland
658,1659,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",101MS325,Biogen,France
658,1659,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",101MS325,Biogen,Hungary
658,1659,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",101MS325,Biogen,Italy
658,1659,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",101MS325,Biogen,Latvia
658,1659,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",101MS325,Biogen,Poland
658,1659,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",101MS325,Biogen,Slovenia
658,1659,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",101MS325,Biogen,Spain
658,1659,NCT01058005,"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",101MS325,Biogen,Sweden
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,205-MS-203,Biogen,Czechia
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,205-MS-203,Biogen,Germany
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,205-MS-203,Biogen,Hungary
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,205-MS-203,Biogen,India
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,205-MS-203,Biogen,Poland
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,205-MS-203,Biogen,Russian Federation
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,205-MS-203,Biogen,Ukraine
659,1660,NCT01051349,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis,205-MS-203,Biogen,United Kingdom
664,1665,NCT00939549,High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis,NA_00016884,Johns Hopkins University,United States
668,1669,NCT00902135,"Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)",14543,Bayer,Germany
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201,Novartis Pharmaceuticals,United States
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201,Novartis Pharmaceuticals,Canada
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201,Novartis Pharmaceuticals,Finland
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201,Novartis Pharmaceuticals,Germany
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201,Novartis Pharmaceuticals,Hungary
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201,Novartis Pharmaceuticals,Italy
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201,Novartis Pharmaceuticals,Norway
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201,Novartis Pharmaceuticals,Poland
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201,Novartis Pharmaceuticals,Russian Federation
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201,Novartis Pharmaceuticals,Spain
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201,Novartis Pharmaceuticals,Switzerland
670,1671,NCT00879658,"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis",CBAF312A2201,Novartis Pharmaceuticals,Turkey
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-202,Biogen,Czech Republic
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-202,Biogen,Germany
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-202,Biogen,Hungary
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-202,Biogen,India
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-202,Biogen,Poland
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-202,Biogen,Russian Federation
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-202,Biogen,Ukraine
671,1672,NCT00870740,Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-202,Biogen,United Kingdom
673,1674,NCT00837785,A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS,109MS101,Biogen,Germany
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,United States
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Australia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Austria
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Belarus
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Belgium
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Bosnia and Herzegovina
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Bulgaria
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Canada
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Croatia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Czechia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Estonia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,France
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Germany
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Greece
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,India
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Ireland
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Israel
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Italy
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Latvia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Mexico
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,"Moldova, Republic of"
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Netherlands
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,New Zealand
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,North Macedonia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Poland
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Puerto Rico
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Romania
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Serbia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Slovakia
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,South Africa
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Spain
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Switzerland
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,Ukraine
674,1675,NCT00835770,BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS),109MS303,Biogen,United Kingdom
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,United States
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Australia
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Belgium
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Canada
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Czechia
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Denmark
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Finland
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,France
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Germany
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Hungary
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Italy
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Netherlands
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Poland
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Spain
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Sweden
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Switzerland
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,Turkey
678,1679,NCT00731692,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",CFTY720D2306,Novartis Pharmaceuticals,United Kingdom
682,1683,NCT00623415,Flupirtine as Oral Treatment in Multiple Sclerosis,2006-005262-39,"Charite University, Berlin, Germany",Germany
684,1685,NCT00574041,How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose,AUS-8002,Biogen,Australia
685,1686,NCT00534261,Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?,BIO-BNL 99-01,Biogen,Belgium
685,1686,NCT00534261,Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?,BIO-BNL 99-01,Biogen,Luxembourg
685,1686,NCT00534261,Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?,BIO-BNL 99-01,Biogen,United Kingdom
686,1687,NCT00525668,Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study),2006-006323-39,"Charite University, Berlin, Germany",Germany
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Argentina
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Australia
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Belgium
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Brazil
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Canada
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Czechia
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Finland
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,France
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Germany
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Greece
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Italy
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Mexico
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Netherlands
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Norway
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Portugal
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Slovakia
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,Spain
687,1688,NCT00493298,Tysabri Observational Program,IMA-06-02,Biogen,United Kingdom
688,1689,NCT00493116,Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta,AUS-8001,Biogen,Australia
688,1689,NCT00493116,Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta,AUS-8001,Biogen,New Zealand
690,1691,NCT00492466,Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies,RECOVER,Biogen,Finland
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,United States
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Belarus
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Belgium
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Bosnia and Herzegovina
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Bulgaria
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Canada
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Costa Rica
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Croatia
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Czech Republic
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Estonia
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,France
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Germany
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Greece
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,India
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Ireland
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Israel
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Latvia
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,"Macedonia, The Former Yugoslav Republic of"
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Mexico
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,"Moldova, Republic of"
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,New Zealand
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Poland
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Puerto Rico
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Romania
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Serbia
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Slovakia
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Spain
691,1692,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,109MS302,Biogen,Ukraine
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,United States
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Australia
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Austria
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Belgium
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Bosnia and Herzegovina
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Canada
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Croatia
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Czech Republic
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,France
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Germany
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Greece
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Guatemala
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,India
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Israel
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Italy
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,"Macedonia, The Former Yugoslav Republic of"
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Mexico
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,"Moldova, Republic of"
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Netherlands
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,New Zealand
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Poland
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Romania
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Serbia
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Slovakia
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,South Africa
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Switzerland
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Ukraine
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,United Kingdom
694,1695,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,109MS301,Biogen,Virgin Islands (U.S.)
697,1698,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-201,Biogen,Czech Republic
697,1698,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-201,Biogen,Germany
697,1698,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-201,Biogen,Hungary
697,1698,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-201,Biogen,India
697,1698,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-201,Biogen,Poland
697,1698,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-201,Biogen,Russian Federation
697,1698,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-201,Biogen,Ukraine
697,1698,NCT00390221,Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis,205-MS-201,Biogen,United Kingdom
703,1704,NCT00317941,Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif,91489,Bayer,France
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Australia
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Belgium
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Canada
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Czech Republic
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Denmark
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Finland
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,France
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Germany
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Greece
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Hungary
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Ireland
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Israel
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Italy
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Netherlands
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,New Zealand
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Poland
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Spain
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Sweden
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Switzerland
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,Turkey
705,1706,NCT00297232,Natalizumab (Tysabri) Re-Initiation of Dosing,101-MS-321,Biogen,United Kingdom
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,NOR-03-01,Biogen,Belgium
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,NOR-03-01,Biogen,Denmark
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,NOR-03-01,Biogen,Finland
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,NOR-03-01,Biogen,Netherlands
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,NOR-03-01,Biogen,Norway
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,NOR-03-01,Biogen,Sweden
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,NOR-03-01,Biogen,Switzerland
720,1721,NCT00168766,Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS,NOR-03-01,Biogen,United Kingdom
722,1723,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,24735,EMD Serono,United States
722,1723,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,24735,EMD Serono,Argentina
722,1723,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,24735,EMD Serono,Austria
722,1723,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,24735,EMD Serono,Brazil
722,1723,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,24735,EMD Serono,France
722,1723,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,24735,EMD Serono,Germany
722,1723,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,24735,EMD Serono,Italy
722,1723,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,24735,EMD Serono,Netherlands
722,1723,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,24735,EMD Serono,Russian Federation
722,1723,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,24735,EMD Serono,Spain
722,1723,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,24735,EMD Serono,Switzerland
722,1723,NCT00078338,Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis,24735,EMD Serono,United Kingdom
725,1726,NCT04792567,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),CBAF312ADE03,Novartis Pharmaceuticals,Germany
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,United States
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Argentina
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Australia
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Austria
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Belarus
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Belgium
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Bulgaria
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Canada
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,China
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Czechia
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Denmark
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Finland
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,France
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Germany
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Greece
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Hungary
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,India
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Israel
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Italy
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Japan
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Lithuania
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Netherlands
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Norway
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Poland
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Portugal
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Romania
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Russian Federation
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Spain
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Turkey
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,Ukraine
726,1727,NCT04411641,Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),EFC16645,Sanofi,United Kingdom
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,United States
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Argentina
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Australia
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Austria
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Belgium
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Bulgaria
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Canada
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,China
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Czechia
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Estonia
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,France
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Germany
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Greece
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Hungary
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Ireland
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Israel
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Italy
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Japan
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Latvia
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Lithuania
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Netherlands
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Poland
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Portugal
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Romania
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Russian Federation
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Slovakia
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Spain
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Sweden
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Switzerland
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,Turkey
736,1737,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),CBAF312A2304,Novartis Pharmaceuticals,United Kingdom
737,1738,NCT01647321,Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis,NA_00069253,Johns Hopkins University,United States
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,United States
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Belgium
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Canada
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Czechia
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Denmark
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Finland
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,France
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Germany
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Ireland
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Israel
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Italy
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Netherlands
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Poland
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Russian Federation
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Spain
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,Sweden
738,1739,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,101MS326,Biogen,United Kingdom
749,1750,NCT04878211,A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,COMB157GUS16,Novartis Pharmaceuticals,United States
750,1751,NCT04667949,Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients,CFTY720D2419,Novartis Pharmaceuticals,China
752,1753,NCT03745144,Effects of Cladribine Tablets on the PK of Microgynon®,MS700568_0031,"Merck KGaA, Darmstadt, Germany",Germany
752,1753,NCT03745144,Effects of Cladribine Tablets on the PK of Microgynon®,MS700568_0031,"Merck KGaA, Darmstadt, Germany",Poland
755,1756,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),MS200136_0035,"Merck KGaA, Darmstadt, Germany",Algeria
755,1756,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),MS200136_0035,"Merck KGaA, Darmstadt, Germany",Argentina
755,1756,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),MS200136_0035,"Merck KGaA, Darmstadt, Germany",Bahrain
755,1756,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),MS200136_0035,"Merck KGaA, Darmstadt, Germany",Bulgaria
755,1756,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),MS200136_0035,"Merck KGaA, Darmstadt, Germany",Egypt
755,1756,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),MS200136_0035,"Merck KGaA, Darmstadt, Germany",Hungary
755,1756,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),MS200136_0035,"Merck KGaA, Darmstadt, Germany","Iran, Islamic Republic of"
755,1756,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),MS200136_0035,"Merck KGaA, Darmstadt, Germany","Korea, Republic of"
755,1756,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),MS200136_0035,"Merck KGaA, Darmstadt, Germany",Kuwait
755,1756,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),MS200136_0035,"Merck KGaA, Darmstadt, Germany",Lebanon
755,1756,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),MS200136_0035,"Merck KGaA, Darmstadt, Germany",Morocco
755,1756,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),MS200136_0035,"Merck KGaA, Darmstadt, Germany",Poland
755,1756,NCT02921035,Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS),MS200136_0035,"Merck KGaA, Darmstadt, Germany",Saudi Arabia
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,United States
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Bosnia and Herzegovina
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Brazil
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Canada
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Colombia
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Costa Rica
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Czechia
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Denmark
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Egypt
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,France
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Germany
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Guatemala
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Hungary
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Ireland
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Italy
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Lebanon
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Mexico
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Morocco
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Netherlands
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Panama
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Poland
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Russian Federation
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Saudi Arabia
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,Spain
756,1757,NCT03523858,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,MN39159,Hoffmann-La Roche,United Arab Emirates
759,1760,NCT01235455,"Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors",14235,Bayer,Portugal
760,1761,NCT01705236,A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®,CFTY720DDE15TS,Novartis Pharmaceuticals,Germany
760,1761,NCT01705236,A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®,CFTY720DDE15TS,Novartis Pharmaceuticals,Switzerland
763,1764,NCT04676555,Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis,COMB157G2004,Novartis Pharmaceuticals,United States
763,1764,NCT04676555,Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis,COMB157G2004,Novartis Pharmaceuticals,Australia
763,1764,NCT04676555,Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis,COMB157G2004,Novartis Pharmaceuticals,United Kingdom
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,United States
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,Australia
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,Austria
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,Canada
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,Denmark
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,France
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,Germany
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,Ireland
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,Italy
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,Netherlands
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,Portugal
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,Spain
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,Switzerland
764,1765,NCT02230969,Plegridy Observational Program,105MS401,Biogen,United Kingdom
765,1766,NCT02097849,Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.,109MS307,Biogen,United States
766,1767,NCT01903291,Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS,109MS404,Biogen,United States
767,1768,NCT01873417,Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States,109MS403,Biogen,United States
768,1769,NCT01216072,"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",CFTY720DUS01,Novartis Pharmaceuticals,United States
768,1769,NCT01216072,"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",CFTY720DUS01,Novartis Pharmaceuticals,Canada
768,1769,NCT01216072,"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",CFTY720DUS01,Novartis Pharmaceuticals,Puerto Rico
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,United States
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Argentina
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Australia
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Austria
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Belgium
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Brazil
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Canada
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Czechia
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Denmark
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Egypt
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Estonia
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Finland
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,France
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Germany
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Greece
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Guatemala
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Hungary
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Ireland
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Israel
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Italy
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Jordan
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,"Korea, Republic of"
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Malaysia
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Netherlands
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Norway
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Panama
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Peru
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Poland
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Portugal
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Romania
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Russian Federation
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Slovakia
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,South Africa
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Spain
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Sweden
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Switzerland
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,Turkey
769,1770,NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,CFTY720D2399,Novartis Pharmaceuticals,United Kingdom
770,1771,NCT00424788,A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS),101MS001,Biogen,United States
772,1773,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,CFTY720D2201E2,Novartis Pharmaceuticals,Canada
772,1773,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,CFTY720D2201E2,Novartis Pharmaceuticals,Denmark
772,1773,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,CFTY720D2201E2,Novartis Pharmaceuticals,France
772,1773,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,CFTY720D2201E2,Novartis Pharmaceuticals,Germany
772,1773,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,CFTY720D2201E2,Novartis Pharmaceuticals,Italy
772,1773,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,CFTY720D2201E2,Novartis Pharmaceuticals,Poland
772,1773,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,CFTY720D2201E2,Novartis Pharmaceuticals,Portugal
772,1773,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,CFTY720D2201E2,Novartis Pharmaceuticals,Spain
772,1773,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,CFTY720D2201E2,Novartis Pharmaceuticals,Switzerland
772,1773,NCT02307838,Long-term Follow-up of Fingolimod Phase II Study Patients,CFTY720D2201E2,Novartis Pharmaceuticals,United Kingdom
773,1774,NCT01978574,Intellectual Enrichment to Build Cognitive Reserve in MS,NMSS-PP1854,Kessler Foundation,United States
775,1776,NCT03623243,"Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients.",CBAF312AUS02,Novartis Pharmaceuticals,United States
775,1776,NCT03623243,"Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients.",CBAF312AUS02,Novartis Pharmaceuticals,Puerto Rico
780,1781,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,205MS305,Biogen,United States
780,1781,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,205MS305,Biogen,Canada
780,1781,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,205MS305,Biogen,Germany
780,1781,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,205MS305,Biogen,Italy
780,1781,NCT02881567,Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab,205MS305,Biogen,Puerto Rico
781,1782,NCT02587065,Plegridy Satisfaction Study in Participants,ITA-PEG-14-10779,Biogen,Italy
785,1786,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,CFTY720D2312,Novartis Pharmaceuticals,United States
785,1786,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,CFTY720D2312,Novartis Pharmaceuticals,Argentina
785,1786,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,CFTY720D2312,Novartis Pharmaceuticals,Brazil
785,1786,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,CFTY720D2312,Novartis Pharmaceuticals,Canada
785,1786,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,CFTY720D2312,Novartis Pharmaceuticals,Chile
785,1786,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,CFTY720D2312,Novartis Pharmaceuticals,Mexico
785,1786,NCT01633112,MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone,CFTY720D2312,Novartis Pharmaceuticals,Puerto Rico
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,CFTY720D2324,Novartis Pharmaceuticals,Australia
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,CFTY720D2324,Novartis Pharmaceuticals,Austria
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,CFTY720D2324,Novartis Pharmaceuticals,Czech Republic
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,CFTY720D2324,Novartis Pharmaceuticals,Finland
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,CFTY720D2324,Novartis Pharmaceuticals,Germany
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,CFTY720D2324,Novartis Pharmaceuticals,Greece
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,CFTY720D2324,Novartis Pharmaceuticals,Hungary
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,CFTY720D2324,Novartis Pharmaceuticals,Israel
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,CFTY720D2324,Novartis Pharmaceuticals,Italy
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,CFTY720D2324,Novartis Pharmaceuticals,Spain
786,1787,NCT01499667,Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod,CFTY720D2324,Novartis Pharmaceuticals,Switzerland
787,1788,NCT01125475,A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects,EMR 701068-521,"Merck KGaA, Darmstadt, Germany",Norway
788,1789,NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",TYS-IMA-08-11,Biogen,Belgium
788,1789,NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",TYS-IMA-08-11,Biogen,Mexico
788,1789,NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",TYS-IMA-08-11,Biogen,Poland
788,1789,NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",TYS-IMA-08-11,Biogen,Romania
788,1789,NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",TYS-IMA-08-11,Biogen,Saudi Arabia
788,1789,NCT00871780,"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",TYS-IMA-08-11,Biogen,Ukraine
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Argentina
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Bahrain
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Belgium
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Bosnia and Herzegovina
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Canada
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,China
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Colombia
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Czech Republic
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Egypt
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Estonia
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,France
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Germany
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,"Iran, Islamic Republic of"
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Israel
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Italy
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Jordan
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,"Korea, Republic of"
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Kuwait
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Lebanon
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Libyan Arab Jamahiriya
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Mexico
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Netherlands
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,New Zealand
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Norway
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Pakistan
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Portugal
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Saudi Arabia
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Singapore
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Slovakia
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Slovenia
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Sweden
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Syrian Arab Republic
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Taiwan
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,United Arab Emirates
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,United Kingdom
789,1790,NCT00787657,Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment,13852,Bayer,Venezuela
790,1791,NCT00428584,RNF and Betaseron® Tolerability Study,27133,EMD Serono,United States
792,1793,NCT04593927,Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients,CBAF312A1401,Novartis Pharmaceuticals,Japan
806,1807,NCT03453125,Improving Learning in Hispanics With TBI or MS,R-799-13,Kessler Foundation,United States
806,1807,NCT03453125,Improving Learning in Hispanics With TBI or MS,R-799-13,Kessler Foundation,Spain
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,MN42989,Hoffmann-La Roche,United States
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,MN42989,Hoffmann-La Roche,Canada
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,MN42989,Hoffmann-La Roche,France
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,MN42989,Hoffmann-La Roche,Germany
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,MN42989,Hoffmann-La Roche,Italy
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,MN42989,Hoffmann-La Roche,Spain
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,MN42989,Hoffmann-La Roche,Switzerland
819,1820,NCT04998851,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,MN42989,Hoffmann-La Roche,United Kingdom
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,MN42988,Hoffmann-La Roche,United States
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,MN42988,Hoffmann-La Roche,France
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,MN42988,Hoffmann-La Roche,Germany
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,MN42988,Hoffmann-La Roche,Italy
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,MN42988,Hoffmann-La Roche,Spain
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,MN42988,Hoffmann-La Roche,Switzerland
820,1821,NCT04998812,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,MN42988,Hoffmann-La Roche,United Kingdom
824,1825,NCT04908891,"A Comprehensive Assessment of Trunk, Scapula and Upper Limb in Neurological Patients. Reliability, Validity and Interrelatedness",Neuro-JR-001,Hasselt University,Belgium
834,1835,NCT04682548,Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients,20-01799,NYU Langone Health,United States
839,1840,NCT04639401,Auditory-motor Coupling in Multiple Sclerosis With Cerebellar Lesions,AMCiMS-001,Hasselt University,Belgium
848,1849,NCT04408274,Remediation of Emotional Deficits in Multiple Sclerosis and Traumatic Brain Injury,R-764-13,Kessler Foundation,United States
872,1873,NCT03951974,A Social Emotion Regulation Intervention in MS,PC 8-19,Kessler Foundation,United States
873,1874,NCT03938558,Art for MS - Controlled Trial,B9115201836892,Hasselt University,Belgium
877,1878,NCT03759249,Sleep Medical Treatment in MS Patients Suffering From Fatigue,SLEEPFAMS,"Charite University, Berlin, Germany",Germany
880,1881,NCT03723356,Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS),17-00238,NYU Langone Health,United States
882,1883,NCT03677440,Exercise Training Effects on Cognition and Brain Function in Multiple Sclerosis: Project EXACT,IRB-300000111,Kessler Foundation,United States
883,1884,NCT03668990,"Feasability, Validty and Reliability of Inertial Sensors",Kinematic01,Hasselt University,Belgium
888,1889,NCT03500289,Ketamine for Treatment of MS Fatigue,IRB00164017,Johns Hopkins University,United States
906,1907,NCT03049969,Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS),16-01810,NYU Langone Health,United States
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,CFTY720D2319,Novartis Pharmaceuticals,United States
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,CFTY720D2319,Novartis Pharmaceuticals,Australia
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,CFTY720D2319,Novartis Pharmaceuticals,Canada
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,CFTY720D2319,Novartis Pharmaceuticals,Czechia
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,CFTY720D2319,Novartis Pharmaceuticals,Denmark
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,CFTY720D2319,Novartis Pharmaceuticals,Germany
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,CFTY720D2319,Novartis Pharmaceuticals,Italy
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,CFTY720D2319,Novartis Pharmaceuticals,Netherlands
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,CFTY720D2319,Novartis Pharmaceuticals,Poland
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,CFTY720D2319,Novartis Pharmaceuticals,Spain
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,CFTY720D2319,Novartis Pharmaceuticals,Switzerland
909,1910,NCT02907281,Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis,CFTY720D2319,Novartis Pharmaceuticals,United Kingdom
914,1915,NCT02833142,"Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes",215HV103,Biogen,United States
917,1918,NCT02740296,Depression and Immune Function in Multiple Sclerosis (MS),DENIM,"Charite University, Berlin, Germany",Germany
922,1923,NCT02538094,tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis,IRB00033581,Johns Hopkins University,United States
940,1941,NCT01918748,Effect of I-TRAVLE Training on Arm Function in MS and Chronic Stroke Patients,I-TRAVLE,Hasselt University,Belgium
940,1941,NCT01918748,Effect of I-TRAVLE Training on Arm Function in MS and Chronic Stroke Patients,I-TRAVLE,Hasselt University,Netherlands
941,1942,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,109MS402,Biogen,United States
941,1942,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,109MS402,Biogen,Australia
941,1942,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,109MS402,Biogen,Canada
941,1942,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,109MS402,Biogen,France
941,1942,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,109MS402,Biogen,Germany
941,1942,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,109MS402,Biogen,Ireland
941,1942,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,109MS402,Biogen,Italy
941,1942,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,109MS402,Biogen,Poland
941,1942,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,109MS402,Biogen,Spain
941,1942,NCT01911767,Biogen Multiple Sclerosis Pregnancy Exposure Registry,109MS402,Biogen,United Kingdom
942,1943,NCT01905527,Adherence Trial With MS LifeLines ® Services,EMR 200136-567,EMD Serono,United States
946,1947,NCT01791244,A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device,EMR 200136-560,"Merck KGaA, Darmstadt, Germany",Germany
946,1947,NCT01791244,A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device,EMR 200136-560,"Merck KGaA, Darmstadt, Germany",Sweden
951,1952,NCT01578330,"A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720",CFTY720DTR01,Novartis Pharmaceuticals,Turkey
953,1954,NCT01532154,Fampridine Pregnancy Exposure Registry,218MS402,Biogen,France
958,1959,NCT01414816,Betaferon® Regulatory Post-Marketing Surveillance,14839,Bayer,"Korea, Republic of"
968,1969,NCT01128075,Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects,EMR701068-520,"Merck KGaA, Darmstadt, Germany",Canada
972,1973,NCT01024777,Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis,NA_00023005,Johns Hopkins University,United States
976,1977,NCT00893217,BEYOND Pilot Study,91232,Bayer,United States
977,1978,NCT00881205,Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment,CENA713DDE18,Novartis Pharmaceuticals,Germany
978,1979,NCT00845338,Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity,12331,Bayer,Germany
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Argentina
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Austria
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Belgium
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Bulgaria
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Canada
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Croatia
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Czech Republic
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Estonia
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Finland
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",France
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Germany
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Greece
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Israel
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Italy
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Latvia
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Lebanon
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Morocco
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Poland
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Portugal
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Romania
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Russian Federation
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Serbia
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Slovakia
980,1981,NCT00813709,Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX),28981,"Merck KGaA, Darmstadt, Germany",Spain
993,1994,NCT05005013,A Teleheath tDCS Approach to Decrease Cannabis Use,21-01028,NYU Langone Health,United States
18,2019,NCT02641041,"Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants",215HV102,Biogen,United Kingdom
30,2031,NCT01864707,Acupuncture or MBSR for Patients With Fatigue and MS,MS-Fatigue-13,"Charite University, Berlin, Germany",Germany
36,2037,NCT01610310,Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers,105HV103,Biogen,United States
43,2044,NCT01031199,Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers,13101,Bayer,Australia
43,2044,NCT01031199,Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers,13101,Bayer,Sweden
63,2064,NCT02988401,Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis,IRB00095554,Johns Hopkins University,United States
64,2065,NCT02506751,Open-label Study of Liothyronine in MS,IRB00061965,Johns Hopkins University,United States
73,2074,NCT01371071,Cohort Study of Clinically Isolated Syndrome and Early Multiple Sclerosis,EK1/2011,"Charite University, Berlin, Germany",Germany
75,2076,NCT02254304,Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™,200136-583,"Merck KGaA, Darmstadt, Germany",Germany
83,2084,NCT05010902,Pregnancy Cohort in Multiple Sclerosis (MS),PreCoMS,"Charite University, Berlin, Germany",Germany
84,2085,NCT02695394,Emotional Processing in Multiple Sclerosis / Clinically Isolated Syndrome: A Neuropsychological fMRI-study,EA1/126/15,"Charite University, Berlin, Germany",Germany
86,2087,NCT02076841,Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen,CHE-AVX-12-10348,Biogen,Czech Republic
86,2087,NCT02076841,Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen,CHE-AVX-12-10348,Biogen,Switzerland
103,2104,NCT01051817,POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler,CAIN457B2201,Novartis Pharmaceuticals,Czech Republic
103,2104,NCT01051817,POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler,CAIN457B2201,Novartis Pharmaceuticals,Russian Federation
103,2104,NCT01051817,POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler,CAIN457B2201,Novartis Pharmaceuticals,Ukraine
104,2105,NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,TYNERGY,Biogen,Austria
104,2105,NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,TYNERGY,Biogen,Denmark
104,2105,NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,TYNERGY,Biogen,Norway
104,2105,NCT00884481,Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS,TYNERGY,Biogen,Sweden
107,2108,NCT01436643,Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression,CFTY720DDE06,Novartis Pharmaceuticals,Germany
140,2141,NCT03418376,Carnosine Loading and Periodized Training in MS and HC,17.09/REVA17.02,Hasselt University,Belgium
156,2157,NCT00772525,Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis,ACT10573,Sanofi,United States
179,2180,NCT00376506,A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia,060212,National Institute of Neurological Disorders and Stroke (NINDS),United States
181,2182,NCT00168714,Pregnancy Exposure Registry for Avonex (Interferon Beta-1a),C-871,Biogen,United States
188,2189,NCT03183791,RELAXaHEAD for Headache Patients,17-00525,NYU Langone Health,United States
191,2192,NCT02504840,Natural History of Multiple Sclerosis and Its Mimickers,150158,National Institute of Neurological Disorders and Stroke (NINDS),United States
207,2208,NCT02301247,Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS),R-839-14,Kessler Foundation,United States
